US20090181451A1 - Specimen sample collection device and test system - Google Patents
Specimen sample collection device and test system Download PDFInfo
- Publication number
- US20090181451A1 US20090181451A1 US12/411,009 US41100909A US2009181451A1 US 20090181451 A1 US20090181451 A1 US 20090181451A1 US 41100909 A US41100909 A US 41100909A US 2009181451 A1 US2009181451 A1 US 2009181451A1
- Authority
- US
- United States
- Prior art keywords
- pad
- absorbent pad
- handle
- collection device
- specimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 169
- 239000002250 absorbent Substances 0.000 claims abstract description 115
- 230000002745 absorbent Effects 0.000 claims abstract description 115
- 239000012530 fluid Substances 0.000 claims abstract description 64
- 238000007906 compression Methods 0.000 claims abstract description 63
- 230000006835 compression Effects 0.000 claims abstract description 63
- 238000004891 communication Methods 0.000 claims abstract description 15
- 239000012491 analyte Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims description 85
- 239000007788 liquid Substances 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 11
- 230000000007 visual effect Effects 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 239000004973 liquid crystal related substance Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 239000004020 conductor Substances 0.000 claims 1
- 230000007246 mechanism Effects 0.000 abstract description 4
- 210000003296 saliva Anatomy 0.000 description 36
- 238000000034 method Methods 0.000 description 30
- 230000009977 dual effect Effects 0.000 description 21
- 241000725303 Human immunodeficiency virus Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000003255 drug test Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000011109 contamination Methods 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 229960004242 dronabinol Drugs 0.000 description 5
- 238000003317 immunochromatography Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 201000009032 substance abuse Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000012863 analytical testing Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000012123 point-of-care testing Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 3
- 229960003614 regadenoson Drugs 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- -1 serum Substances 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000012125 lateral flow test Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- 101100129336 Dictyostelium discoideum malA gene Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001326189 Gyrodactylus prostae Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 101100190460 Shigella flexneri pic gene Proteins 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 238000003677 abuse test Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 101150086151 hrdB gene Proteins 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940018389 oraline Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 101150102864 rpoD gene Proteins 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 101150117326 sigA gene Proteins 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5029—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures using swabs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B2010/0003—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements including means for analysis by an unskilled person
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/025—Displaying results or values with integrated means
- B01L2300/027—Digital display, e.g. LCD, LED
Definitions
- the present invention relates to devices and methods for the collection of fluids, and more particularly to devices and methods for the collection of fluids and methods for testing samples so obtained for fluids including bodily fluids such as saliva.
- confirmation is carried out using gas chromatography-mass spectrometry (GC-MS), gas chromatography-mass spectrometry-mass-spectrometry (GC-MS-MS) or liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) on a second sample taken from the subject.
- GC-MS gas chromatography-mass spectrometry
- LC-MS-MS liquid chromatography-mass spectrometry-mass spectrometry
- SAMHSA The United States Substance Abuse Mental Health Services Administration
- saliva or oral fluids
- hair and sweat These guidelines define the need for (1) a confirmatory specimen to be collected at the time of the initial sampling, (2) defined specimen volumes to be collected and (3) expected drug cut-off values, among other requirements.
- NASH National Institutes of Health
- NIDCR National Institute of Dental and Craniofacial Research
- the insurance testing industry uses saliva as a sample matrix for applicants wishing to purchase specific life insurance policies as a safeguard measure prior to writing policies. In these situations applicants are tested for HIV, cotinine (nicotine) and cocaine using a testing device called “OraSure” from OraSure Technologies, which collects oral fluids for subsequent testing under laboratory conditions. Each of the major insurance testing laboratories in the United States performs a significant number of oral fluid tests on an annual basis.
- OraSure Technologies was successful in gaining FDA approval for its OraQuick® HIV 1/2 rapid test for oral fluid diagnosis of the HIV viruses type 1 and type 2. Previously the test had been approved by the agency for whole blood, serum and plasma only.
- drugs of abuse are routinely detected from oral fluids collected in the workplace, in criminal justice settings and in hospitals using OraSure Technologies' “InterceptTM” device and associated range of ELISA microplate assays. In this case a panel of 5 “abused” drugs or more are measured under laboratory conditions.
- Rapid testing devices using saliva have recently appeared, which may be used at the “point-of-care”. These devices can collect and perform immediate testing for several drugs of abuse but these suffer from poor performance for certain tests at the present time, particularly Tetrahydrocannabinol (THC) or its major metabolite 11-nor- ⁇ 9-Tetrahydrocannabinol.
- THC Tetrahydrocannabinol
- Examples of this type of device are the OraTectTM test from Branan Medical Corporation, the OraLine assay from Sun Biomedical and the Cozart BioScience RapiScan device, among others.
- the FDA has approved a laboratory HIV test, OraSure HIV-1 for testing for the HIV-1 virus from oral fluid as well as a Western blot confirmatory test, which also uses oral fluids. Both have been used in a Public Health setting in the United States for over five (5) years.
- immunoglobulins for example sigA (for use in psychological disorders, stress and athletic performance), therapeutic drugs (for instance lithium, theophylline, AZT), tumor markers (e.g. Her-2/neu), bacterial antibodies such as helicobacter pylori and even genomic detection of mitochondrial DNA (for criminal justice applications) using oral fluids as the preferred specimen matrix.
- therapeutic drugs for instance lithium, theophylline, AZT
- tumor markers e.g. Her-2/neu
- bacterial antibodies such as helicobacter pylori
- genomic detection of mitochondrial DNA for criminal justice applications
- saliva is viewed as a viable sample matrix for testing purposes.
- a number of devices in use today have provided means for the collection of bodily fluids including saliva and urine among others.
- One FDA-cleared fluid collection device used predominantly for saliva collection and testing has been shown to be potentially unsafe in pediatric patients.
- the Saliva•SamplerTM device from SDS, Inc. utilizes perforations present on filter paper to facilitate removal of the filter paper for subsequent saliva separation and testing.
- the device is placed under the tongue to accumulate sublingual whole saliva, collected by leaving the sampling device, consisting of a filter paper material attached to a plastic stem, in position until a sample indicator built into the device changes color confirming sample sufficiency.
- the process requires that the subject not chew, bite or unnecessarily move the device during the collection procedure. In pediatric patients, particularly, this can be a problem as children have a tendency to chew on materials placed in the oral cavity. In infants, separation of the filter paper prematurely can result in choking.
- an alternate FDA-approved oral fluid collection system from OraSure Technologies, Inc. incorporates salts impregnated on to the collection medium in the form of a “hypertonic” solution.
- OraSure® incorporates salts impregnated on to the collection medium in the form of a “hypertonic” solution.
- the purpose of the salts is to facilitate ready absorption of oral fluids (oral mucosal transudate) from the gingival crevices and thereby reduce sampling time.
- the taste of the salts on the device medium may be distasteful to potential users.
- ICT tests are now available including as examples OraSure Technologies' rapid oral fluid test, OraQuick HIV 1/2, Quidel Corporation's Quick-Vue Streptococcus A and Helicobacter pylori rapid tests, Meridian BioSciences' ImmunoCard assays for Respiratory Syncticial Virus (RSV) and Clostridium Difficile ( C. Difficile ) and Roche Diagnostics' TestCup drugs of abuse tests among a multitude of others.
- RSV Respiratory Syncticial Virus
- C. Difficile Clostridium Difficile
- Roche Diagnostics' TestCup drugs of abuse tests among a multitude of others.
- OraSure Technologies has been successful in commercializing a rapid, oral fluid test, OraQuick HIV 1/2, despite the fact that oral fluid, point-of-care tests represent an attractive alternative to current testing methodologies. This may be due, in part, to current data requirements for approval of rapid tests in the U.S. This is expected to change as a result of OraSure's success with OraQuick® HIV 1/2 and the emergence of saliva-based drug testing assays.
- Cozart BioSciences UK, www.Cozart.co.uk
- RapiScan a hand-held device known as RapiScan
- This reading system is not fully integrated and requires a separate collection step prior to testing the specimen.
- OraSure Technologies www.OraSure.com
- sample collection is distinct from the specimen testing process.
- SAMHSA has proposed in its 2004 guidelines for alternate specimen testing that minimum oral fluid collection volumes are to be 2 mL of clean specimen.
- None of the available prior art provides for expressing an oral fluid sample from a subject directly onto a diagnostic test strip, providing a mechanism for determining sample volume adequacy and visually reading qualitative and/or quantitative results from the test strip through a small window in an integrated one-step manner.
- a specimen sample collection device includes a handle having a sufficiency indicator and an absorbent pad partially contained within said handle.
- a specimen sample collection device and test system includes a handle having a sufficiency indicator, an absorbent pad partially contained within said handle, a pad compression tube insertable over said absorbent pad within said handle and around an end of said handle, and a collection tube having one or more sample chambers, attachable to said pad compression tube, and wherein said compression tube defines one or more chambers, and wherein when said collection tube is attached to said pad compression tube, the chambers are in fluid communication with said pad compression tube.
- a specimen sample collection device including a sufficiency indicator made up of a light pipe indicator window.
- a specimen sample collection device including a bar code identification.
- a specimen sample collection device and test system including a lock and key securing mechanism.
- a specimen sample collection device including a handle one or more analyte test strips
- the specimen sample collection device and test system of the present invention presents numerous advantages, including: (1) ability to collect appropriate volumes of specimen sample and confirmation sample using a split (fork-shaped) collection medium; (2) ergonomically correct design; (3) simple to use; (4) ability to adapt to new testing requirements; (5) sample containment with minimized chance of contamination; (6) utilizes an absorbent pad collection medium rather than a filter paper collection medium; (7) provides a unique sample indicator design that does not utilize a compressible sponge or polymeric bead; (8) provides a unique sample indicator design that does not involve disposing an indicator on filter paper; (9) provides a unique sample indicator design that does not require an adequacy indicator separate from the collection medium; (10) utilizes a collection medium that does not require a rectangular or paddle shape; (11) allows for samples to be removed from individual compartments or chambers and channeled directly or pipetted if necessary, directly into an alternate receptacle for further analysis or testing; (12) allows for removal of the specimen directly using high-throughput automated equipment, which can speed up sampling and analysis tremendous
- (13) allows for collection of mutually distinct samples for initial testing or analysis and follow up or supplementary testing either immediately or at a later date;
- (14) allows for use of “tailored” buffer solutions designed to protect the integrity of various different analytes or samples collected; (15) utilizes multiple absorbent materials to maximize the retention and release properties of the invention; (16) allows for testing samples collected immediately using available lateral flow immunochromatographic test strips to deliver test results at the point of care; (17) allows for collection of specimen without the need for an additional filtration or centrifugation step; (18) requires no expensive capital equipment to collect and process the sample; (19) allows for individual sample identification; (20) allows for a variety of sample collection tubes to be attached to the end of the invention depending upon sample volume requirements and whether single or dual sampling is required; (21) requires minimum manipulation of fluid specimen; (22) minimizes the chance for contamination of the sample collected; (23) minimizes the chance of tampering with the sample collected; (24) provides the ability to rule out contamination; (25) reduces the opportunity for misdiagnosis; (26) provides the ability to
- FIG. 1 shows an embodiment of a specimen sample collection device and test system.
- FIG. 2 shows a light pipe indicator window over a dry absorbent pad.
- FIG. 3 shows a light pipe indicator window over a saturated absorbent pad
- FIG. 4 shows another view of a specimen sample collection device.
- FIGS. 5 a , 5 b , and 5 c show different views of a pad compression tube.
- FIG. 5 c shows the view of FIG. 5 a from the side.
- FIGS. 6 a , 6 b , and 6 c show different views of a chambered collection tube.
- FIG. 6 b shows the view of FIG. 6 a from the side.
- FIG. 7 shows a schematic view of a specimen sample collection device and test system with a pad compression tube attached to a handle.
- FIG. 8 shows another embodiment of a specimen sample collection device and test system.
- FIG. 9 shows another embodiment of a specimen sample collection device and test system.
- FIG. 10 shows the interior layout of a specimen sample collection device.
- FIG. 11 shows an embodiment of an absorbent pad.
- FIG. 12 shows another embodiment of an absorbent pad.
- a specimen sample collection device 10 includes a handle 14 with a sufficiency indicator, such as a light pipe indicator window 18 , and an absorbent pad, which can be a rounded tongue absorbent pad 15 .
- a specimen sample collection device and test system 12 includes a specimen sample collection device 10 , a pad compression tube, which can be a dual outlet single channel compression tube 20 , and a collection tube, which can be a chambered collection tube 26
- Absorbent pad fits partially within the handle. As shown in FIGS. 1 , 4 , 7 , and 10 at 15 , absorbent pad can be rounded to provide the advantage of comfort to the sample subject. As shown in FIGS. 8 and 9 at 115 , the absorbent pad can be split, i.e., divided into two parts and connected at the base of the pad to allow for dual sample collection.
- the split absorbent pad 115 can be prong- or fork-shaped or have splits of varying length. Those of skill in the art are aware that the absorbent pad can be divided into more than two parts.
- the split absorbent pad 115 is configured such that one prong of the pad can absorb at least 1.0 mL of specimen, and the other pad can absorb at least 0.5 mL of specimen, when a highly absorbent pad material e.g. Ahlstrom 320 or Schleicher & Schuell 300 grades are chosen.
- a split, divided, prong or fork shaped absorbent pad is placed into the test subject's mouth each split or division of said absorbent pad absorbs saliva at the same time, thus collecting identical saliva samples.
- the absorbent pad could be two or more separate and distinct absorbent pads.
- Absorbent pad can also be provided with a bifurcated-end in a smooth “m” shape on the end of the pad interior of the handle to deliver saliva to the ends of two test strips simultaneously.
- the absorbent pad soaks up specimen when placed in a specimen atmosphere, such as for example, soaking up saliva when placed in a subject's mouth, preferably under the tongue.
- Absorbent pad is not filter paper. Filter paper is designed specifically to have porous openings to have control or “filter” the size of material passing through it.
- the purpose of the absorbent pad is to collect and disperse a high volume of liquid sample yet remain relatively rigid through the sample collection procedure.
- an advantage is obtained by using an absorbent pad rather than filter paper.
- Absorbent pad may be a variety of different materials that will absorb liquid and release or transmit said liquid following an action carried out to facilitate removal of said liquid from the pad.
- Pad materials have a variety of properties, which may affect the ability of a substance to adhere (or bind) to that specific absorbent pad material effectively, and also for that material to be suitably released from the pad when required.
- One particular property is a material's hydrophobic or hydrophilic characteristics. Hydrophilic materials are readily “wet” with aqueous solutions and so aqueous based fluids, such as saliva, urine, whole blood, vaginal fluid, etc. (containing antibodies, minerals, and other analytes of interest, will be readily absorbed by hydrophilic pad materials and released effectively.
- absorbent pad material is made up of hydrophilic materials from a list including Ahlstrom materials catalog numbers 270 and 320, Schleicher & Schuell catalog numbers 300 and 900 among others. Experimentation has shown that a large cross-section of substances to be detected or measured in fluids can be carried out using one of these versatile products. Hydrophobic pad materials will not adequately “wet” in aqueous solutions but will be wetted in low surface tension liquids such as alcohols, hence the need for the addition of low alcohol concentrations in any buffering system used.
- the properties of these materials vary from absorbent materials with low protein binding capability to those with high binding capacity. Materials are available in various thicknesses and sizes and may be easily customized to suit the specific intended application for the pad material. Already, a diverse range of product materials is available form several sources including Schleicher & Schuell, Ahlstrom, Filtrona, Porex, Whatman and others as described above. These materials are typically manufactured under strictly controlled conditions to ensure uniform composition and absorption/release of fluids from the pad. Several of the afore-mentioned materials have been widely used as diagnostic and analytical testing components and have been certified as suitable for these purposes.
- absorbent pad materials may also include hydrophilic or hydrophobic components bound, or integrated into the material, such components being capable of modifying the absorption and release characteristics of the absorbent pad as well as the speed of uptake of the sample fluid under consideration.
- hydrophobic materials including progesterone, testosterone, estradiol, other steroid hormones and ⁇ 9-Tetrahydrocannabinol (THC)
- THC ⁇ 9-Tetrahydrocannabinol
- the binding characteristics of various protein and other molecules to the absorbent pad is another important factor. This particular property influences the nature of the binding of a given material to absorbent pad materials and is carefully considered when choosing products for a given application. Materials with high-binding characteristics may in some instances be used to encourage removal of certain analytes from the oral cavity, which may be difficult to obtain using pad materials with lower binding characteristics. In these cases, release agents such as alcohols, Tween 20 and others may be used.
- thermal stability Other properties, which can impact the performance of absorbent materials and hence the ability to collect an optimum fluid specimen include thermal stability, pore size and pad size.
- modification of the properties of the absorbent pad can be made by the addition of various agents at the time of manufacturing the pad material.
- This invention has been conceived as a means of providing a method for customization and optimization of the properties of pad materials for a wide range of specific applications for which fluid collection is required.
- modification of the dimensions of the pad can modify the absorption characteristics of the pad material. Materials such as those cited here are available through a number of companies including Whatman (UK), Ahlstrom (Finland), Schleicher and Schuell (US), Porex and Filtrona (US), which are chosen here by way of examples.
- An embodiment of this invention therefore, teaches a method of using alternate pad materials in order to obtain the optimum system for collection and subsequent testing or analysis of certain hormones, drugs and any materials likely to cause difficulty in analyte removal from the pad.
- the ability to provide flexible options for pad materials is a novel invention.
- An advantage of this is that the pad material may be modified and optimized to suit the subsequent analysis, testing, or other action to be performed.
- absorbent pad can be a folded in half providing a double layer absorbent pad to provide additional structure for the absorbent pad and increase the surface area and absorption volume.
- FIG. 11 at 200 shows one possible shape, with the pad folded upon itself along the fold line at 202 , which can be used with the specimen sample collective device 10 .
- FIG. 12 at 204 shows a split absorbent pad shape, with the pad folded upon itself along the fold line at 206 .
- absorbent pads can be folded in a number of ways to reach the result of providing a double layer absorbent pad for additional structure and an increase in the surface area and absorption volume.
- sufficiency indicator is preferably a shaped light pipe 18 with a color or indicator on one end 18 a , which is placed in contact with the absorbent pad 15 . It is preferably made of styrolux. As show in FIGS. 2 , 3 , when the absorbent pad is saturated with sufficient sample, the reflectance of the pad changes causing a change in the refractive properties of the light pipe, seen as an altering of the color or indicator, which is seen as a line 18 b .
- the indicator is capable of distinguishing and providing a visual indication between a dry and wet absorbent pad.
- the absorbent pad is opaque when dry and provides a good reflecting surface. However, when the absorbent pad becomes wet, the pad develops a surface film of liquid and also become translucent. This reduces the absorbent pad's reflective ability and the line 18 b is no longer visible to the user.
- the sufficiency indicator can be a molded or otherwise manufactured window, convex side downward, and frosted or textured such that when absorbent pad expands by absorption of sufficient sample, the wet absorbent pad touches the inside of the indicator resulting in a change in window clarity, clear spot or symbol indicating that adequate sample volume has been achieved.
- an expandable material in contact with an absorbent pad expands behind and obscures an indicator providing a visual indication that sample volume is adequate when an adequate sample content is reached.
- the sufficiency indicator can be a clear window with a small absorbent pad with a colored dot on the inward side, attached on the inside of the window.
- the absorbent pad expands against the absorbent paper, the liquid from that pad is transferred to the absorbent paper. Becoming wet, the absorbent pad becomes translucent during which time the colored dot becomes visible through the absorbent paper and becomes visible in the sample adequacy indicator.
- the sufficiency indicator can be coated on the inside with a chemically neutral hydrochromic material such that when absorbent pad swells with sample it absorbs, the swollen pad touches the inside of the indicator, reacting with the coating and causing a color change or graphic symbol to appear.
- a chemically neutral hydrochromic material such that when absorbent pad swells with sample it absorbs, the swollen pad touches the inside of the indicator, reacting with the coating and causing a color change or graphic symbol to appear.
- the sufficiency indicator is a simple Liquid Crystal Display (LCD) device with two bi polar metal leads pressing into the absorbent pad.
- LCD Liquid Crystal Display
- the pad is of adequate saturation, galvanic action causes a small electrical current to flow between the metal leads causing the LCD to darken.
- the sufficiency indicator is configured as a snap-up indicator that includes a plastic spring set in a sponge-like material.
- Sponge-like material can be any material that when moistened loses structural rigidity and softens. When material is softened by sample, for instance saliva, one part of the “spring” disengages from the sponge and snaps providing visual indication that sample volume is adequate.
- Fluids are removed from absorbent pads by squeezing sample from the pad material through compression tubes. Alternate methods of fluid removal may be envisaged as necessary to facilitate removal of said liquid from the pad. Such techniques include vortexing, squeezing, centrifugation and treatment with an agent to promote removal of non-constituent components of the pad material among others. Pushing the handle into the pad compression tube compresses the absorbent pad expelling specimen from absorbent pad into the pad compression tube. As shown in FIG. 7 , pad compression tube 20 when inserted over absorbent pad 15 and on end of handle 14 is in fluid communication with absorbent pad 15 .
- Pad compression tube can have one or more channels and one or more outlets.
- FIG. 8 shows a dual outlet dual channel pad compression tube 120 having two outlets 122 a , 122 b .
- FIG. 9 shows a single outlet single channel pad compression tube 150 with a single outlet 152 .
- FIGS. 1 , 5 a , 5 b , 5 c , and 7 show a dual outlet single channel pad compression tube 20 with two outlets 22 a , 22 b.
- pad compression tube 20 fits over and around the absorbent pad 15 , which is partially contained within the handle 14 (see also FIG. 10 ), and tube 20 goes over the end of the handle 14 .
- handle 114 can be provided with a ridged lock 160 which fits in a depressed key 162 on a pad compression tube 120 . Pad is pushed into pad compression tube until “locked” into place for safety preventing contamination and infectious transfer.
- Pad compression tubes are is made of polypropylene or acrylic or other suitable material. Pad compression tubes can be provided with a tube cap, see 24 in FIG. 1 made of polypropylene or other suitable material.
- a dual outlet dual channel pad compression tube 120 fits around a split absorbent pad 115 . Pushing the handle 114 into the dual outlet dual channel pad compression tube 120 compresses the split absorbent pad 115 , expelling specimen from split absorbent pad 115 into the dual outlet dual channel pad compression tube 120 . Dual outlet dual channel pad compression tube 120 when inserted over split absorbent pad 115 and on end of handle 114 is in fluid communication with split absorbent pad 115 . As shown in FIG. 8 , the dual outlet dual channel pad compression tube 120 includes a structural barrier 140 hat separates the two parts of the split absorbent pad 115 , such that when the pad 115 is compressed upon entry into the compression tube 120 , the saliva sample from each said part of the pad 115 remains distinct and separate. Next, each separated saliva sample flows or is compressed into its own Eppendorf-style collection tube 126 , which is attached to a compression tube, see 120 in FIG. 8 and 150 in FIG. 9 .
- the pad compression tube outlets can also each contain a particulate filter (not shown). Each distinct and separate saliva sample passes through its own particulate filter remaining distinct and separate.
- the pad compression tube can contain a buffer solution to stabilize the sample obtained for analysis or testing.
- Suitable buffers include an aqueous solution with any of a variety of salts including sodium chloride, sodium phosphate, ethylene diamine tetra acetic acid (EDTA) salts or others.
- Buffer solution may contain a preservative to maintain the integrity of the sample and minimize degradation. This preservative serves to inhibit proteolytic properties of enzyme materials that can cause destruction of the antibody molecules being tested with the device over time.
- the types of compounds that can be considered as conferring preservative properties include enzyme inhibitors, anti-bacterial agents, bacteriostatic molecules, and anti-fungal compounds among others. Within the sub-group of bacteriostatic molecules, there are a number which can be added to also inhibit the growth of microorganisms. Such compounds include ProClin® (in various formulations) sodium azide and thimerosal.
- the buffer solution may also include a detergent material, which improves antibody removal from the absorbent pad material, when desired.
- a detergent material which improves antibody removal from the absorbent pad material, when desired.
- Preferred examples of this are Tween-20 (chemical name polyoxyethylene sorbitan monooleate) and sodium dodecyl sulfate (SDS), although other examples, e.g. Triton X-100, chlorhexidine and others may also be used.
- Tween-20 for example, is also useful for prevention of non-specific binding of required antibody molecules to unwanted solid surfaces. Typical concentrations of Tween-20, for instance, necessary to achieve the desired effect, range from 0.1%-1%.
- low molecular weight alcohols ethanol, methanol, butanol, etc.
- low concentrations 0.1-4.0%) can be introduced as additional analyte-releasing agents, depending upon the material under investigation.
- the pad collection tube may contain no reagent or liquid whatsoever.
- the pad collection tube may contain a non-fluid containing buffer, i.e. a buffer without liquid, commonly referred to as a “dry buffer”. The permutation and concentrations of any agents used as part of the collection procedure will be optimized for the collection of specific target molecules.
- Typical buffers include phosphate buffered saline consisting of, for example: 10 mmol/L Sodium Phosphate Dibasic; 150 mmol/L Sodium Chloride; 5 mmol/L Disodium Ethylenediamine Tetraacetate (EDTA); 31 mmol/L Sodium Azide; Adjusted to neutral pH of 7.2
- Collection tubes can be a chambered collection tube 26 , as shown in FIGS. 1 , 6 a , 6 b , and 6 c , or individual collection tubes 126 , as shown in FIGS. 8 and 9 .
- Chambered collection tube 26 is shown in different views in FIGS. 6 a , 6 b , 6 c .
- Collection tubes fit over the end of the pad compression tube and have one or more chambers for receiving and holding collected samples. These chambers or compartments are separated allowing samples to remain distinct and free from contamination.
- collection tube, at 26 in FIG. 1 and at 126 in FIGS. 8 and 9 when inserted on end of pad compression tube, 20 in FIG. 1 , 120 in FIG. 8 , and 150 in FIG. 9 is in fluid communication with pad compression tube.
- Collection tube, at 26 in FIG. 1 and at 126 in FIGS. 8 and 9 can be provided with a tube cap, at 28 in FIG. 1 , and at 128 in FIGS. 8 and 9 , sealing the tubes.
- Eppendorf-type collection tubes 126 collect the separate and distinct saliva samples once they pass through a pad compression tube.
- Eppendorf-type collection tubes 126 are conical at their closed end, round at the open end, and comprised of flexible lids 128 that remain attached to the tube 126 whether open or closed.
- the Eppendorf-type collection tubes 126 may be attached together on the outside surface.
- the Eppendorf-type collection tubes 126 remain inwardly distinct in that each receives one of the distinct and separate saliva samples and said samples remain separate and distinct once in the Eppendorf-type collection tubes 126 .
- the Eppendorf-type collection tube lid 128 is then closed, retaining the fluid sample's integrity and quantity.
- Handles, pad compression tubes, and collection tube can be made using any number of different processes familiar to those with skill in the art, such as by injection molding, compression molding, casting; incorporating materials such as thermoplastics, thermosets, glass, metal, etc.
- the light pipe indicator window can be made of clear material-glass, plastic, Perspex; sample sufficiency indicator changes color or when something is moved, i.e., changes condition.
- handle is made of two elongated pieces of General Purpose Styrene which fit together over a portion of the absorbent pad. See FIG. 10 .
- Handle is preferably made of two pin and ultrasonically assembled halves. Those of skill in the art know that the handle can be made of any one of numerous materials.
- absorbent pad is placed in the mouth under the tongue. Absorbent pad expands when a specimen sample is received. When indicator indicates sufficient sample has been obtained, Indicator provides a visual indication of the same.
- the specimen sample collection device is taken and “swabbed” once across the gums from one side to the other, then reversed and swabbed across the gum line a second time in the opposite direction.
- the specimen sample collection device In order to collect saliva, the specimen sample collection device is placed under the tongue and allowed to remain there until the visual indicator in the device—a light pipe showing a blue coloration—disappears completely.
- the typical collection time for sample adequacy is in the range of 1-2 minutes.
- the disappearance of the visual indicator may be observed by a second person or in the event of the sample being collected in the privacy of the home, by a donor in isolation
- the device may be removed from the mouth to visually inspect for the disappearance of the color and replaced under the tongue immediately without detriment to the collection or subsequent test procedure.
- the user places the pad 115 into the dual outlet pad compression tube 115 with the split end facing downwards, and places the Eppendorf-type collection tube 126 on the outlets 122 of the dual outlet pad compression tube 120 , and pushes on handle 114 , forcing the pad 115 all the way down to the bottom of the compression tube 120 until the end of the handle 114 can be pushed no closer to the bottom of the compression tube 120 .
- Pushing expels specimen from split absorbent pad 115 , which then travels in fluid communication through the dual outlet pad compression tube 120 , through the outlets 122 and into collection tubes 126 .
- the collection tubes 126 thus provide samples for supplemental or confirmatory testing as well as for independent storage or transportation. Two samples are thus provided. Depending upon the dimensions and type of pad material used the individual forks of the absorbent material will release between 0.3 ml and 2 ml of pure saliva. In instances where the individual samples, are to be transported to a laboratory or remote location, or are not for immediate testing, a preservative buffer may be introduced either in the compression tube or the collection receptacles to maintain the integrity of the sample so collected.
- the buffer may be a liquid or dry buffer. In instances where the samples are to be tested immediately, or at the point-of-care, the device may be supplied without buffer.
- graduated tubes such as small Eppendorf tubes, available “off the shelf” from a number of vendors, may be used.
- the collection tube can be a single channel collection receptacle or Eppendorf tube.
- customized collection tubes may be adapted for use with the invention.
- Each of the tubes used in connection with the collection tool are fitted with individual caps for sealing purposes. These caps may be tamper-proof for evidentiary purposes.
- the pad compression tube can be provided with a cap or caps for sealing.
- the specimen sample collection device 10 can be provided with one or more lateral flow test strips 16 a , 16 b in the handle 14 in fluid communication with the absorbent pad 15 by one or more membranes 17 a , 17 b .
- Such tests strips for example ICT strips are commonly used in the diagnostic industry today, to screen for a plethora of diseases including HIV, streptococcus A & B, hepatitis A, B & C, cardiac markers (e.g. troponin I, troponin T, myoglobin), tumor markers (e.g. prostate specific antigen (PSA), alpha-fetoprotein (AFP), etc.), glucose, cholesterol and others.
- PSA prostate specific antigen
- AFP alpha-fetoprotein
- test strip is coated or “striped” with one or more analyte of interest, together with a control material usually Protein A-gold coated to human IgG to verify that the test strip is working appropriately.
- a control material usually Protein A-gold coated to human IgG to verify that the test strip is working appropriately.
- Protein A-gold coated to human IgG to verify that the test strip is working appropriately.
- Such strips are now very commonly available and well characterized. After a short period of time (which may vary from 2 to 20 minutes), a Control Line will appear on the test strip, and in instances of a positive specimen a second line (the Test Line) will appear indicating positivity for the analyte of interest.
- the test strip is comprised of reagents that test qualitatively (for the presence or absence of analytes or substances) and/or semi-quantitatively (providing an estimate of the quantity) of the chemical(s)/substances for which the device tests within the fluid sample.
- the test strip is located in the collector handle housing, above the attachment loci of the absorbent pad.
- the collector handle housing has a window-type opening above a portion of the test strip through which results from the test strip can be viewed.
- a reagent test strip comprised of at least one reagent chemical that upon contact with the chemical for which it tests or a by-product of the chemical for which it tests in the testing fluid, undergoes a chemical reaction which produces or activates an indicator, preferably visual, of the presence or absence and/or quantity of the chemical for which it tests.
- the test system may be applied to a number of different diseases, and analytical tests, which includes HIV, drugs of abuse, bacteria, viruses, environmental toxins and others. Reaction times and run times will vary depending upon the characteristics of individual test strips, which are optimized to achieved maximum sensitivity and specificity.
- the characteristics of each individual test will be defined in the respective package insert for the products, however, as an example, an HIV test optimized for oral fluid detection using the specimen sample collection device will provide results within a period of 10-20 minutes with a sensitivity greater than 95% and a specificity of greater than 99%. What should be understood in the case of an HIV test is that the appearance of a Test Line in the presence of a Control Line is indicative of an initially positive or non-negative result.
- test strips When more than one test strip is provided they are arranged side-by-side on the handle 14 , as shown in FIGS. 4 and 10 , at 16 a , 16 b .
- saliva collected in identical fashion to the embodiments described above is transferred to two test strips instead of one by two membranes, 17 a , 17 b .
- a multiplicity of analytes, for instance drugs of abuse including but not limited to the NIDA-5 series of drugs, benzodiazepines, Oxycodone, and others, as well as therapeutic drugs and multiple infectious diseases for instance may be detected simultaneously using a single oral fluid collection device and test system.
- Test strips for the NIDA-5 series of drugs have been optimized in the specimen sample collection device to run within 15 minutes from the time sample adequacy has been achieved.
- the reagent test strips 16 are located in the collector handle 14 housing with a window-type opening 60 above each test strip 16 , or, alternatively, a single window-type opening above all the test strips.
- Each test strip contains a reagent test for analyzing the qualitative (presence or absence) and/or quantitative data of the chemical for which it tests within the fluid sample.
- each test strip may test for a different chemical or the same chemical as any other test strip.
- the test strips extend linearly down the length of the collector handle housing, parallel to one another. In another embodiment, the test strips may be adjacent to one, two or more additional test strips.
- the results may be read visually or may be read by electronic reading devices including pocket-PC devices, PDAs and others.
- a pocket-PC driven system utilizes proprietary software to digitally record images from the lateral flow test strips.
- the reader combines a “Pocket PC” (PDA-sized) reading system, printing device, camera and software, capable of reading multiple lines within a pre-set reading window.
- a plastic cap is placed over the absorbent collection pad of the specimen sample collection device, if desired, then the opposite end of the device (handle-first) is inserted into the port of the hand-held reading device.
- the reading device initially does a diagnostic “self test” to ensure that the reader is working appropriately then performs a read out of the intensity of the coloration of the individual line (or lines) on the test strip (or strips).
- the results of this are fed automatically to a printing device, which prints out a permanent record of the results for each drug or other analyte being tested.
- the visual appearance of a line, or the confirmation of a line in the case of drug tests using the hand-held reading system is an indication that the test is negative or non-positive for that particular analyte or drug. This is the opposite of what one would find for similar tests for HIV and other analytes where the presence of a Test Line in the presence of a Control Line is indicative of a positive or non-negative result.
- the invention provides visually read, qualitative results, which may be quantitated using available electronic, digital or other format readers. These in turn may be either small, PDA-sized (hand-held) systems or portable and non portable instruments that utilize electromagnetic radiation, chemiluminescence, digital photography and other techniques, while providing a digital printout of the quantitative results obtained.
- Eppendorf tube Fluid forced through separate porous filters in pad compression tube and into mutually distinct gradiated Eppendorf-type tubes attached to the pad compression tube outlets. Each Eppendorf tube is then bar coded.
- a bar code may further be provided on the specimen sample collection device handle. A recess is molded into the specimen sample collection device handle and the bar code is imprinted thereon.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
A specimen sample collection device and test system includes a handle having a sufficiency indicator, an absorbent pad partially contained within said handle, a pad compression tube insertable over said absorbent pad within said handle and around an end of said handle, and a collection tube having one or more sample chambers, attachable to said pad compression tube, and wherein said compression tube defines one or more chambers, and wherein when said collection tube is attached to said pad compression tube, the chambers are in fluid communication with said pad compression tube. A specimen sample collection device including a sufficiency indicator made up of a light pipe indicator window. A specimen sample collection device including an absorbent pad split and divided into two lengths connected at a base. A specimen sample collection device including a bar code identification. A specimen sample collection device and test system including a locking mechanism. A specimen sample collection device including a handle having one or more analyte test strips therein. A specimen sample collection device and test system including a reader.
Description
- The present application is a Continuation of, and claims benefit of priority to, U.S. Non-provisional patent application Ser. No. 11/045,180, filed Jan. 27, 2005, which claims the benefit of and priority to prior co-pending U.S. Provisional Patent Application Ser. Nos. 60/539,929 filed on Jan. 28, 2004, and 60/630,613 filed on Nov. 23, 2004. The teachings of application Ser. Nos. U.S. 60/539,929, U.S. 60/630,613, and U.S. Ser. No. 11/045,180 are hereby incorporated by reference into this application.
- The present invention relates to devices and methods for the collection of fluids, and more particularly to devices and methods for the collection of fluids and methods for testing samples so obtained for fluids including bodily fluids such as saliva.
- Traditional methods of testing for diseases, drugs and other antigens in humans have up until the last few years been predominantly done using blood samples. These samples collected in laboratories at the request of physicians require that blood drawn by a trained phlebotomist is sent to a laboratory and the serum component comprising a predominance of immunoglobulins, containing antibodies to the disease or disease state in question, is tested using a variety of available test kits to assist in the diagnosis of various diseases including infectious diseases, cardiovascular diseases, cancers and many others. Such samples can also be tested for the presence of non-disease analytes such as metals, minerals, DNA, bacteria and organic molecules among others.
- Under current standardized laboratory practices, it is necessary to confirm any initially positive result obtained from diagnostic or analytical testing with a more sensitive (accurate) method. This, in fact is true for most, if not all diagnostic tests used today, including, as an example, HIV tests, which are confirmed by more definitive methods such as Western blot techniques or immunofluorescence (IFA) assays. In the case of drug tests, for instance, performed in criminal justice settings (at the police car, in correctional facilities, in drug courts, etc.) or at the workplace, by way of two examples, confirmation is carried out using gas chromatography-mass spectrometry (GC-MS), gas chromatography-mass spectrometry-mass-spectrometry (GC-MS-MS) or liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) on a second sample taken from the subject. Other diagnostic and screening methods require similarly accurate methods for confirmatory purposes.
- The United States Substance Abuse Mental Health Services Administration (SAMHSA), the designated body responsible for regulating Federal drug testing in the United States, has recently prepared guidelines for the introduction of new tests and sample collection procedures for drug tests using so-called, “alternate” specimens. These sample types include saliva (or oral fluids), hair and sweat. These guidelines define the need for (1) a confirmatory specimen to be collected at the time of the initial sampling, (2) defined specimen volumes to be collected and (3) expected drug cut-off values, among other requirements.
- The need for duplicate, or a multiplicity of mutually distinct samples taken from the same source at the same time is part of a general trend being observed in many areas of the diagnostic and analytical testing businesses. The main reason for this increasingly important trend is the legal implication of being able to definitively rule out any potential contamination of the test sample during the testing process. The obvious consequences of an incorrect diagnosis of HIV for a patient or erroneous DNA results in the case of a criminal case are just two examples of where 100% certainty of sample integrity are paramount and are contributing reasons for the development of this particular invention. This potential legal implication has had an impact on general testing protocols and as a result healthcare and other professionals are now more cognizant than ever of the need to collect a “pure” sample or samples then ensure that those samples are analyzed to produce accurate results. During the testing process absolute “chain-of-custody” rules are enforced to ensure that no adulteration or contamination of the specimen occurs. This is not always possible in current testing protocols as there are opportunities for sample contamination or sample tampering. This is true for any test whether done on blood, serum, saliva, nasal secretions, vaginal discharge or any other sample where information obtained relates to a diagnosis of disease or disease state. Such information is taken in conjunction with any additional information available to the person making a decision relating to interpretation of the results obtained.
- Despite the fact that saliva has been used as a diagnostic fluid since Ancient Chinese times, when the “Rice Test” (which relied on the inhibition of saliva as a determinate of guilt) was used, it is only over the last few years that salivary testing has taken on much greater significance. There are several important factors, which have contributed to this change: (1) The increase in popularity of non- or less-invasive testing methods; (2) the availability of more sensitive antibodies and antigens for detection of immunoglobulins in saliva; (3) new technologies in the area of point-of-care testing; (4) a need for more rapid results; (5) acquisition of serum/blood involves patient discomfort and can cause difficulty particularly where young children or intravenous drug users are concerned; (6) use of venous blood to collect serum requires capital equipment and involves an initial processing step, which adds significant time to result turnaround and has additional cost implications and also; (7) a general movement away from centralized laboratory testing towards “near-patient” testing, also called “point-of-care” testing.
- The National Institutes of Health (NIH) recognized the value of salivary testing as early as 1993 and recent symposia orchestrated by this organization, for instance a meeting held in 1999, organized by NIH's National Institute of Dental and Craniofacial Research (NIDCR) division has helped increase the profile of testing using oral fluids. NIH, through various divisions, has since been encouraging companies with expertise in this area to apply for funding for new projects aimed at introducing novel tests using non-invasive samples for laboratory and point-of-care applications.
- The insurance testing industry uses saliva as a sample matrix for applicants wishing to purchase specific life insurance policies as a safeguard measure prior to writing policies. In these situations applicants are tested for HIV, cotinine (nicotine) and cocaine using a testing device called “OraSure” from OraSure Technologies, which collects oral fluids for subsequent testing under laboratory conditions. Each of the major insurance testing laboratories in the United States performs a significant number of oral fluid tests on an annual basis.
- In April 2004 OraSure Technologies was successful in gaining FDA approval for its OraQuick® HIV 1/2 rapid test for oral fluid diagnosis of the HIV viruses type 1 and type 2. Previously the test had been approved by the agency for whole blood, serum and plasma only.
- In a separate area drugs of abuse are routinely detected from oral fluids collected in the workplace, in criminal justice settings and in hospitals using OraSure Technologies' “Intercept™” device and associated range of ELISA microplate assays. In this case a panel of 5 “abused” drugs or more are measured under laboratory conditions.
- Rapid testing devices using saliva have recently appeared, which may be used at the “point-of-care”. These devices can collect and perform immediate testing for several drugs of abuse but these suffer from poor performance for certain tests at the present time, particularly Tetrahydrocannabinol (THC) or its major metabolite 11-nor-Δ9-Tetrahydrocannabinol. Examples of this type of device are the OraTect™ test from Branan Medical Corporation, the OraLine assay from Sun Biomedical and the Cozart BioScience RapiScan device, among others.
- Up until now urine based rapid drug testing has been performed preferentially due to availability, cost, and to a certain extent, a lack of salivary tools incorporating some of the features described in this invention. While rapid urine kits are widespread they suffer from issues related to “chain-of-custody”, the need for facilities to collect urine specimens discreetly under appropriate supervision and are easily adulterated by knowledgeable users, who can “cheat” such tests.
- Electronic reading, hand-held devices, such as the Cozart BioSciences RapiScan instrument are also now available outside of the United States, that allow immediate drug testing to be done from oral fluids at the roadside and other field settings. This technology requires sample collection from the donor then immediate testing on site. This concept may well be duplicated in the future, as technologies to “miniaturize” testing platforms, improves.
- The FDA has approved a laboratory HIV test, OraSure HIV-1 for testing for the HIV-1 virus from oral fluid as well as a Western blot confirmatory test, which also uses oral fluids. Both have been used in a Public Health setting in the United States for over five (5) years.
- In addition the FDA has also approved saliva tests for pre-term labor (SalESt™, salivary estriol, from Biex, Inc), a salivary alcohol test (QED®, OraSure Technologies), a cortisol assay (Salimetrics, Inc.) as well as a panel of saliva-based drug assays (Intercept, OraSure Technologies) through the 510(k) clearance system. A number of other oral fluid drug testing products are undergoing regulatory approval, so in the next 12-24 months we might expect to see several other products available in the U.S. Furthermore, “investigational use” tests are available for immunoglobulins, for example sigA (for use in psychological disorders, stress and athletic performance), therapeutic drugs (for instance lithium, theophylline, AZT), tumor markers (e.g. Her-2/neu), bacterial antibodies such as helicobacter pylori and even genomic detection of mitochondrial DNA (for criminal justice applications) using oral fluids as the preferred specimen matrix.
- Emerging methodologies based on microfluidic technology requiring only small quantities of specimen samples are approaching the market. These devices work on virtually any specimen matrix including, but not limited to, saliva, urine, whole blood, serum, and other fluids. Such techniques have already found use in the arena of biodefense monitoring, high throughput screening methods, high performance liquid chromatography (HPLC) and other analytical techniques. These devices, which are being developed in one particular area for use by special intelligence forces, who are required to test for chemical and biological agents in soil, water and other samples before troops arrive at a battle site or during peacekeeping to monitor biological or environmental samples, may be seen as another area where this invention will find application.
- These are a few of the many instances where saliva is viewed as a viable sample matrix for testing purposes. A number of devices in use today have provided means for the collection of bodily fluids including saliva and urine among others. One FDA-cleared fluid collection device used predominantly for saliva collection and testing has been shown to be potentially unsafe in pediatric patients. The Saliva•Sampler™ device from SDS, Inc. utilizes perforations present on filter paper to facilitate removal of the filter paper for subsequent saliva separation and testing. The device is placed under the tongue to accumulate sublingual whole saliva, collected by leaving the sampling device, consisting of a filter paper material attached to a plastic stem, in position until a sample indicator built into the device changes color confirming sample sufficiency. The process requires that the subject not chew, bite or unnecessarily move the device during the collection procedure. In pediatric patients, particularly, this can be a problem as children have a tendency to chew on materials placed in the oral cavity. In infants, separation of the filter paper prematurely can result in choking.
- In another previously described example, an alternate FDA-approved oral fluid collection system from OraSure Technologies, Inc., known as OraSure®, incorporates salts impregnated on to the collection medium in the form of a “hypertonic” solution. According to the manufacturers, the purpose of the salts is to facilitate ready absorption of oral fluids (oral mucosal transudate) from the gingival crevices and thereby reduce sampling time. In practice when the OraSure® device is placed in the oral cavity, the taste of the salts on the device medium may be distasteful to potential users.
- These and other currently available devices fail to address a growing need for efficient collection of bodily fluids including saliva for applications including analytical or diagnostic testing under laboratory, field or point-of-care testing conditions, for instance, whereby a pure sample of fluid, for example saliva, is collected from a subject and split into multiple chambers, thereby providing a means for initial specimen testing analysis or storage, for confirmation or supplementary testing and simultaneously providing a mechanism for confirming sample sufficiency prior to any subsequent testing or analysis of the constituents of the bodily fluid so collected.
- Lateral flow immunochromatography (ICT) tests have been around for over a decade and are a direct descendent of thin-layer chromatography (TLC) techniques pioneered during the 1970s. The technology offers some benefits including cost efficiencies, user-friendliness and the availability of immediate test results. Over the last decade in particular, the availability of high quality raw material components, the growing movement towards near patient or point-of-care (“POC”) testing, coupled with a need for rapid results, has led to an “explosion” in the development and commercialization of both flow-through and lateral flow devices based on immunochromatographic test principles. These devices form part of a rapidly growing industry for diagnostic tests performed outside of the laboratory.
- A variety of ICT tests are now available including as examples OraSure Technologies' rapid oral fluid test, OraQuick HIV 1/2, Quidel Corporation's Quick-Vue Streptococcus A and Helicobacter pylori rapid tests, Meridian BioSciences' ImmunoCard assays for Respiratory Syncticial Virus (RSV) and Clostridium Difficile (C. Difficile) and Roche Diagnostics' TestCup drugs of abuse tests among a multitude of others.
- Technologies other than ICT are equally adaptable to rapid testing. These include latex agglutination, dot-blot tests, microarrays and others.
- Of the above rapid test examples and those currently in existence, only OraSure Technologies has been successful in commercializing a rapid, oral fluid test, OraQuick HIV 1/2, despite the fact that oral fluid, point-of-care tests represent an attractive alternative to current testing methodologies. This may be due, in part, to current data requirements for approval of rapid tests in the U.S. This is expected to change as a result of OraSure's success with OraQuick® HIV 1/2 and the emergence of saliva-based drug testing assays.
- In order to meet the needs of a growing Public Health demand in the U.S. it is important for would-be manufacturers to integrate test strip technologies similar to those mentioned above with a simple-to-use, integrated platform system that can deliver rapid test results, safely and cost-effectively, for a range of diseases or analytes in a non-invasive manner. This is especially important in view of Centers for Disease Control (CDC) estimates that suggest that, of 2.1 million people tested at Publicly-funded Government testing sites using traditional (laboratory) testing methods in the US for the HIV virus, approximately 33% do not return to receive their results and may unwittingly go on to infect others if they are in fact HIV-positive. As the key to all disease prevention is early detection, accurate and early detection using rapid tests can have a major impact on reducing disease incidence.
- In needle-averse populations, for instance, small children, pregnant women and hemophiliacs, the opportunity to provide oral fluid or saliva collection and immediate testing as an alternative to blood-based systems would be welcomed. Similarly general practitioners and health professionals would see an opportunity to provide testing opportunities in non-traditional testing sites, such as in the privacy of the patient's home, in nursing homes, remote clinic settings and even over the counter in a pharmacy environment.
- Cozart BioSciences (UK, www.Cozart.co.uk)) has described the use of a hand-held device known as RapiScan, which tests for several illicit drug entities from oral fluids. This reading system is not fully integrated and requires a separate collection step prior to testing the specimen. OraSure Technologies (www.OraSure.com) has also described in a recent US patent application, the use of a sample collector and test device. In this example also, sample collection is distinct from the specimen testing process.
- SAMHSA has proposed in its 2004 guidelines for alternate specimen testing that minimum oral fluid collection volumes are to be 2 mL of clean specimen.
- None of the available prior art provides for expressing an oral fluid sample from a subject directly onto a diagnostic test strip, providing a mechanism for determining sample volume adequacy and visually reading qualitative and/or quantitative results from the test strip through a small window in an integrated one-step manner.
- The following represents a list of known related art U.S. Pat. No. 5,283,038 issued Feb. 1, 1994, U.S. Pat. No. 5,260,031 issued Nov. 9, 1993, U.S. Pat. No. 5,268,148 issued Dec. 7, 1993, U.S. Pat. No. 5,393,496 issued Feb. 23, 1995, U.S. Pat. No. 5,380,492 issued Jan. 10, 1995, U.S. Pat. No. 5,376,337 issued Dec. 27, 1994, U.S. Pat. No. 6,267,722, U.S. Pat. No. 6,027,943, U.S. Pat. No. 6,187,598, U.S. Pat. No. 5,965,453, U.S. Pat. No. 5,393,496, U.S. Pat. No. 4,943,522, U.S. Pat. No. 4,895,808, U.S. Pat. No. 6,372,516, U.S. Pat. No. 6,046,058, U.S. Pat. No. 5,962,336, U.S. Pat. No. 5,238,652, U.S. patent application Ser. No. 10/061,036 by Lloyd Simonson, U.S. patent application Ser. No. 10/060,605 by Lloyd Simonson, U.S. Pat. No. 6,627,152, U.S. Pat. No. 6,727,879, U.S. Pat. No. 5,922,614 to Edward Cesarczyk, U.S. Pat. No. 6,489,172. The teachings of each of the above-listed citations (which does not itself incorporate essential material by reference) are herein incorporated by reference. None of the above inventions and patents, taken either singularly or in combination, is seen to describe the instant invention as claimed.
- A specimen sample collection device includes a handle having a sufficiency indicator and an absorbent pad partially contained within said handle. A specimen sample collection device and test system includes a handle having a sufficiency indicator, an absorbent pad partially contained within said handle, a pad compression tube insertable over said absorbent pad within said handle and around an end of said handle, and a collection tube having one or more sample chambers, attachable to said pad compression tube, and wherein said compression tube defines one or more chambers, and wherein when said collection tube is attached to said pad compression tube, the chambers are in fluid communication with said pad compression tube. A specimen sample collection device including a sufficiency indicator made up of a light pipe indicator window. A specimen sample collection device including an absorbent pad split and divided into two lengths connected at a base. A specimen sample collection device including a bar code identification. A specimen sample collection device and test system including a lock and key securing mechanism. A specimen sample collection device including a handle one or more analyte test strips A specimen sample collection device and test system including a reader.
- The specimen sample collection device and test system of the present invention presents numerous advantages, including: (1) ability to collect appropriate volumes of specimen sample and confirmation sample using a split (fork-shaped) collection medium; (2) ergonomically correct design; (3) simple to use; (4) ability to adapt to new testing requirements; (5) sample containment with minimized chance of contamination; (6) utilizes an absorbent pad collection medium rather than a filter paper collection medium; (7) provides a unique sample indicator design that does not utilize a compressible sponge or polymeric bead; (8) provides a unique sample indicator design that does not involve disposing an indicator on filter paper; (9) provides a unique sample indicator design that does not require an adequacy indicator separate from the collection medium; (10) utilizes a collection medium that does not require a rectangular or paddle shape; (11) allows for samples to be removed from individual compartments or chambers and channeled directly or pipetted if necessary, directly into an alternate receptacle for further analysis or testing; (12) allows for removal of the specimen directly using high-throughput automated equipment, which can speed up sampling and analysis tremendously. (13) allows for collection of mutually distinct samples for initial testing or analysis and follow up or supplementary testing either immediately or at a later date; (14) allows for use of “tailored” buffer solutions designed to protect the integrity of various different analytes or samples collected; (15) utilizes multiple absorbent materials to maximize the retention and release properties of the invention; (16) allows for testing samples collected immediately using available lateral flow immunochromatographic test strips to deliver test results at the point of care; (17) allows for collection of specimen without the need for an additional filtration or centrifugation step; (18) requires no expensive capital equipment to collect and process the sample; (19) allows for individual sample identification; (20) allows for a variety of sample collection tubes to be attached to the end of the invention depending upon sample volume requirements and whether single or dual sampling is required; (21) requires minimum manipulation of fluid specimen; (22) minimizes the chance for contamination of the sample collected; (23) minimizes the chance of tampering with the sample collected; (24) provides the ability to rule out contamination; (25) reduces the opportunity for misdiagnosis; (26) provides the ability to work within “chain-of-custody” protocols; (27) provides the ability to a rapid test result and a confirmatory result; (28) utilizes an intact pad material and does not require that the absorbent pad material be separated from the main sampling device, so there is a significantly reduced chance of the pad separating in the subject's mouth when used in normal practice; (29) does not require the use of any salts or hypotonic solutions impregnated in the collection medium to improve collection time; (30) ability to deliver fluids to two test strips or two separate receiving ports at the same time.
- Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention may be realized and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims. Further benefits and advantages of the embodiments of the invention will become apparent from consideration of the following detailed description given with reference to the accompanying drawings, which specify and show preferred embodiments of the present invention.
-
FIG. 1 shows an embodiment of a specimen sample collection device and test system. -
FIG. 2 shows a light pipe indicator window over a dry absorbent pad. -
FIG. 3 shows a light pipe indicator window over a saturated absorbent pad -
FIG. 4 shows another view of a specimen sample collection device. -
FIGS. 5 a, 5 b, and 5 c show different views of a pad compression tube. -
FIG. 5 c shows the view ofFIG. 5 a from the side. -
FIGS. 6 a, 6 b, and 6 c show different views of a chambered collection tube. -
FIG. 6 b shows the view ofFIG. 6 a from the side. -
FIG. 7 shows a schematic view of a specimen sample collection device and test system with a pad compression tube attached to a handle. -
FIG. 8 shows another embodiment of a specimen sample collection device and test system. -
FIG. 9 shows another embodiment of a specimen sample collection device and test system. -
FIG. 10 . shows the interior layout of a specimen sample collection device. -
FIG. 11 shows an embodiment of an absorbent pad. -
FIG. 12 shows another embodiment of an absorbent pad. - Before beginning a detailed description of the subject invention, mention of the following is in order. When appropriate, like reference materials and characters are used to designate identical, corresponding, or similar components in differing figure drawings. The figure drawings associated with this disclosure typically are not drawn with dimensional accuracy to scale, i.e., such drawings have been drafted with a focus on clarity of viewing and understanding rather than dimensional accuracy.
- As shown in
FIGS. 1 , 4, a specimensample collection device 10 includes ahandle 14 with a sufficiency indicator, such as a lightpipe indicator window 18, and an absorbent pad, which can be a rounded tongueabsorbent pad 15. As shown inFIG. 1 , a specimen sample collection device andtest system 12 includes a specimensample collection device 10, a pad compression tube, which can be a dual outlet singlechannel compression tube 20, and a collection tube, which can be a chamberedcollection tube 26 - Absorbent pad fits partially within the handle. As shown in
FIGS. 1 , 4, 7, and 10 at 15, absorbent pad can be rounded to provide the advantage of comfort to the sample subject. As shown inFIGS. 8 and 9 at 115, the absorbent pad can be split, i.e., divided into two parts and connected at the base of the pad to allow for dual sample collection. The splitabsorbent pad 115 can be prong- or fork-shaped or have splits of varying length. Those of skill in the art are aware that the absorbent pad can be divided into more than two parts. In this embodiment the splitabsorbent pad 115 is configured such that one prong of the pad can absorb at least 1.0 mL of specimen, and the other pad can absorb at least 0.5 mL of specimen, when a highly absorbent pad material e.g. Ahlstrom 320 or Schleicher & Schuell 300 grades are chosen. When a split, divided, prong or fork shaped absorbent pad is placed into the test subject's mouth each split or division of said absorbent pad absorbs saliva at the same time, thus collecting identical saliva samples. One of skill in the art would also realize that the absorbent pad could be two or more separate and distinct absorbent pads. Absorbent pad can also be provided with a bifurcated-end in a smooth “m” shape on the end of the pad interior of the handle to deliver saliva to the ends of two test strips simultaneously. - The absorbent pad soaks up specimen when placed in a specimen atmosphere, such as for example, soaking up saliva when placed in a subject's mouth, preferably under the tongue. Absorbent pad is not filter paper. Filter paper is designed specifically to have porous openings to have control or “filter” the size of material passing through it. The purpose of the absorbent pad is to collect and disperse a high volume of liquid sample yet remain relatively rigid through the sample collection procedure. Thus, an advantage is obtained by using an absorbent pad rather than filter paper. Absorbent pad may be a variety of different materials that will absorb liquid and release or transmit said liquid following an action carried out to facilitate removal of said liquid from the pad.
- Pad materials have a variety of properties, which may affect the ability of a substance to adhere (or bind) to that specific absorbent pad material effectively, and also for that material to be suitably released from the pad when required. One particular property is a material's hydrophobic or hydrophilic characteristics. Hydrophilic materials are readily “wet” with aqueous solutions and so aqueous based fluids, such as saliva, urine, whole blood, vaginal fluid, etc. (containing antibodies, minerals, and other analytes of interest, will be readily absorbed by hydrophilic pad materials and released effectively. In the preferred embodiment of this invention for example, absorbent pad material is made up of hydrophilic materials from a list including Ahlstrom materials catalog numbers 270 and 320, Schleicher & Schuell catalog numbers 300 and 900 among others. Experimentation has shown that a large cross-section of substances to be detected or measured in fluids can be carried out using one of these versatile products. Hydrophobic pad materials will not adequately “wet” in aqueous solutions but will be wetted in low surface tension liquids such as alcohols, hence the need for the addition of low alcohol concentrations in any buffering system used.
- Those skilled in the art know that numerous materials meeting these requirements exist, such as various cotton linters, for example Schleicher & Schuell (US) papers 300, 900, 903 or 2992, fiber composite materials such as materials available from Ahlstrom (US) for instance Ahlstrom 270, a multi-purpose cellulose material that has been used for fluid collection and release and Ahlstrom grade 320 material, a material with hydrophobic characteristics. Also glass fiber, certain polymeric materials, spunbound polyester materials (e.g. Hollytex brand from Ahlstrom, (US), extruded fibers, other cellulose papers manufactured from raw material cellulose (e.g. Ahlstrom Paper group (US) and Filtrona (US) Transorb® materials), mixed fiber papers (e.g. Whatman (UK) Pads S9036-2009) as well as two-ply materials for example. The properties of these materials vary from absorbent materials with low protein binding capability to those with high binding capacity. Materials are available in various thicknesses and sizes and may be easily customized to suit the specific intended application for the pad material. Already, a diverse range of product materials is available form several sources including Schleicher & Schuell, Ahlstrom, Filtrona, Porex, Whatman and others as described above. These materials are typically manufactured under strictly controlled conditions to ensure uniform composition and absorption/release of fluids from the pad. Several of the afore-mentioned materials have been widely used as diagnostic and analytical testing components and have been certified as suitable for these purposes. Those skilled in the art know that absorbent pad materials may also include hydrophilic or hydrophobic components bound, or integrated into the material, such components being capable of modifying the absorption and release characteristics of the absorbent pad as well as the speed of uptake of the sample fluid under consideration. In the majority of cases antibodies minerals and substances will be readily removed from the absorbent pad upon squeezing the pad in the compression tube according to the operational instructions supplied herein. However, in certain instances, materials that are difficult to remove e.g. hydrophobic materials including progesterone, testosterone, estradiol, other steroid hormones and Δ9-Tetrahydrocannabinol (THC), will be collected in a further embodiment using a pad with hydrophobic properties. In this embodiment a small percentage of low molecular weight alcohol (ethanol, methanol or butanol, for instance) at a concentration of 0.1%-4.0% is added.
- The binding characteristics of various protein and other molecules to the absorbent pad is another important factor. This particular property influences the nature of the binding of a given material to absorbent pad materials and is carefully considered when choosing products for a given application. Materials with high-binding characteristics may in some instances be used to encourage removal of certain analytes from the oral cavity, which may be difficult to obtain using pad materials with lower binding characteristics. In these cases, release agents such as alcohols,
Tween 20 and others may be used. - Other properties, which can impact the performance of absorbent materials and hence the ability to collect an optimum fluid specimen include thermal stability, pore size and pad size. The dimensions and materials used in the preferred embodiments of this invention including Ahlstrom 270 & 320, Schleicher & Schuell 300 & 900 cellulose materials and others have been well characterized by the manufacturers and are also available in published works.
- To one skilled in the art there are also a spread of materials, which offer a choice of “wicking rate”, meaning the rate at which sample fluid is absorbed by the paper or pad material, so it is important for optimization purposes to work with individual manufacturers of such products to choose the optimum characteristics necessary to achieve the best results.
- To one skilled in the art it is further apparent that modification of the properties of the absorbent pad can be made by the addition of various agents at the time of manufacturing the pad material. This invention has been conceived as a means of providing a method for customization and optimization of the properties of pad materials for a wide range of specific applications for which fluid collection is required. Further it is understood by one skilled in the art that modification of the dimensions of the pad (for instance thickness, width, height and others) can modify the absorption characteristics of the pad material. Materials such as those cited here are available through a number of companies including Whatman (UK), Ahlstrom (Finland), Schleicher and Schuell (US), Porex and Filtrona (US), which are chosen here by way of examples. While the above list of materials is considerable, these may or may not be suitable for the collection of certain types of specimens in fluids, for example steroid hormones, THC and certain other drug substances and others, for instance, which have a tendency to “stick to” certain pad materials and can be bound tightly. An embodiment of this invention therefore, teaches a method of using alternate pad materials in order to obtain the optimum system for collection and subsequent testing or analysis of certain hormones, drugs and any materials likely to cause difficulty in analyte removal from the pad. The ability to provide flexible options for pad materials is a novel invention. An advantage of this is that the pad material may be modified and optimized to suit the subsequent analysis, testing, or other action to be performed.
- In an alternative embodiment, as shown in
FIGS. 11 , 12, absorbent pad can be a folded in half providing a double layer absorbent pad to provide additional structure for the absorbent pad and increase the surface area and absorption volume.FIG. 11 at 200 shows one possible shape, with the pad folded upon itself along the fold line at 202, which can be used with the specimen samplecollective device 10.FIG. 12 at 204 shows a split absorbent pad shape, with the pad folded upon itself along the fold line at 206. Those skilled in the art will know that absorbent pads can be folded in a number of ways to reach the result of providing a double layer absorbent pad for additional structure and an increase in the surface area and absorption volume. - As shown in
FIGS. 2 , 3, 4, sufficiency indicator is preferably a shapedlight pipe 18 with a color or indicator on oneend 18 a, which is placed in contact with theabsorbent pad 15. It is preferably made of styrolux. As show inFIGS. 2 , 3, when the absorbent pad is saturated with sufficient sample, the reflectance of the pad changes causing a change in the refractive properties of the light pipe, seen as an altering of the color or indicator, which is seen as aline 18 b. The indicator is capable of distinguishing and providing a visual indication between a dry and wet absorbent pad. The absorbent pad is opaque when dry and provides a good reflecting surface. However, when the absorbent pad becomes wet, the pad develops a surface film of liquid and also become translucent. This reduces the absorbent pad's reflective ability and theline 18 b is no longer visible to the user. - Alternatively, the sufficiency indicator can be a molded or otherwise manufactured window, convex side downward, and frosted or textured such that when absorbent pad expands by absorption of sufficient sample, the wet absorbent pad touches the inside of the indicator resulting in a change in window clarity, clear spot or symbol indicating that adequate sample volume has been achieved. In this embodiment, an expandable material in contact with an absorbent pad, expands behind and obscures an indicator providing a visual indication that sample volume is adequate when an adequate sample content is reached.
- Alternatively, the sufficiency indicator can be a clear window with a small absorbent pad with a colored dot on the inward side, attached on the inside of the window. When the absorbent pad expands against the absorbent paper, the liquid from that pad is transferred to the absorbent paper. Becoming wet, the absorbent pad becomes translucent during which time the colored dot becomes visible through the absorbent paper and becomes visible in the sample adequacy indicator.
- Alternatively, the sufficiency indicator can be coated on the inside with a chemically neutral hydrochromic material such that when absorbent pad swells with sample it absorbs, the swollen pad touches the inside of the indicator, reacting with the coating and causing a color change or graphic symbol to appear. Those skilled in the art know that many different chemically neutral hydrochromic coating materials can be used which would not alter the test samples.
- Alternatively, the sufficiency indicator is a simple Liquid Crystal Display (LCD) device with two bi polar metal leads pressing into the absorbent pad. When the pad is of adequate saturation, galvanic action causes a small electrical current to flow between the metal leads causing the LCD to darken.
- Alternatively, referring to
FIG. 13 , the sufficiency indicator is configured as a snap-up indicator that includes a plastic spring set in a sponge-like material. Sponge-like material can be any material that when moistened loses structural rigidity and softens. When material is softened by sample, for instance saliva, one part of the “spring” disengages from the sponge and snaps providing visual indication that sample volume is adequate. - Fluids are removed from absorbent pads by squeezing sample from the pad material through compression tubes. Alternate methods of fluid removal may be envisaged as necessary to facilitate removal of said liquid from the pad. Such techniques include vortexing, squeezing, centrifugation and treatment with an agent to promote removal of non-constituent components of the pad material among others. Pushing the handle into the pad compression tube compresses the absorbent pad expelling specimen from absorbent pad into the pad compression tube. As shown in
FIG. 7 ,pad compression tube 20 when inserted overabsorbent pad 15 and on end ofhandle 14 is in fluid communication withabsorbent pad 15. - Pad compression tube can have one or more channels and one or more outlets.
FIG. 8 shows a dual outlet dual channel pad compression tube 120 having two outlets 122 a, 122 b.FIG. 9 shows a single outlet single channelpad compression tube 150 with asingle outlet 152.FIGS. 1 , 5 a, 5 b, 5 c, and 7 show a dual outlet single channelpad compression tube 20 with twooutlets - As seen in
FIG. 7 ,pad compression tube 20 fits over and around theabsorbent pad 15, which is partially contained within the handle 14 (see alsoFIG. 10 ), andtube 20 goes over the end of thehandle 14. As shown in the embodiment inFIG. 8 , handle 114 can be provided with aridged lock 160 which fits in adepressed key 162 on a pad compression tube 120. Pad is pushed into pad compression tube until “locked” into place for safety preventing contamination and infectious transfer. - Pad compression tubes are is made of polypropylene or acrylic or other suitable material. Pad compression tubes can be provided with a tube cap, see 24 in
FIG. 1 made of polypropylene or other suitable material. - A dual outlet dual channel pad compression tube 120 fits around a split
absorbent pad 115. Pushing thehandle 114 into the dual outlet dual channel pad compression tube 120 compresses the splitabsorbent pad 115, expelling specimen from splitabsorbent pad 115 into the dual outlet dual channel pad compression tube 120. Dual outlet dual channel pad compression tube 120 when inserted over splitabsorbent pad 115 and on end ofhandle 114 is in fluid communication with splitabsorbent pad 115. As shown inFIG. 8 , the dual outlet dual channel pad compression tube 120 includes astructural barrier 140 hat separates the two parts of the splitabsorbent pad 115, such that when thepad 115 is compressed upon entry into the compression tube 120, the saliva sample from each said part of thepad 115 remains distinct and separate. Next, each separated saliva sample flows or is compressed into its own Eppendorf-style collection tube 126, which is attached to a compression tube, see 120 inFIG. 8 and 150 inFIG. 9 . - The pad compression tube outlets can also each contain a particulate filter (not shown). Each distinct and separate saliva sample passes through its own particulate filter remaining distinct and separate.
- The pad compression tube can contain a buffer solution to stabilize the sample obtained for analysis or testing. Suitable buffers include an aqueous solution with any of a variety of salts including sodium chloride, sodium phosphate, ethylene diamine tetra acetic acid (EDTA) salts or others. Buffer solution may contain a preservative to maintain the integrity of the sample and minimize degradation. This preservative serves to inhibit proteolytic properties of enzyme materials that can cause destruction of the antibody molecules being tested with the device over time. The types of compounds that can be considered as conferring preservative properties include enzyme inhibitors, anti-bacterial agents, bacteriostatic molecules, and anti-fungal compounds among others. Within the sub-group of bacteriostatic molecules, there are a number which can be added to also inhibit the growth of microorganisms. Such compounds include ProClin® (in various formulations) sodium azide and thimerosal.
- The buffer solution may also include a detergent material, which improves antibody removal from the absorbent pad material, when desired. Preferred examples of this are Tween-20 (chemical name polyoxyethylene sorbitan monooleate) and sodium dodecyl sulfate (SDS), although other examples, e.g. Triton X-100, chlorhexidine and others may also be used. Tween-20 for example, is also useful for prevention of non-specific binding of required antibody molecules to unwanted solid surfaces. Typical concentrations of Tween-20, for instance, necessary to achieve the desired effect, range from 0.1%-1%. Similarly, low molecular weight alcohols (ethanol, methanol, butanol, etc.) in low concentrations (0.1-4.0%) can be introduced as additional analyte-releasing agents, depending upon the material under investigation.
- Those skilled in the art will know that there are many possible agents capable of being used as “buffering components”. Alternately the pad collection tube may contain no reagent or liquid whatsoever. Alternately, the pad collection tube may contain a non-fluid containing buffer, i.e. a buffer without liquid, commonly referred to as a “dry buffer”. The permutation and concentrations of any agents used as part of the collection procedure will be optimized for the collection of specific target molecules. In the case of analytes or materials that are difficult to release from the pad material under “normal” buffer conditions, for example “sticky” materials such as the drug THC, or steroid hormones (including testosterone, estradiol, progesterone and others), various reagents including small quantities (less than 5%) of an alcohol, e.g. methanol, ethanol, propanol, iso-propanol may be added to facilitate analyte release.
- Typical buffers include phosphate buffered saline consisting of, for example: 10 mmol/L Sodium Phosphate Dibasic; 150 mmol/L Sodium Chloride; 5 mmol/L Disodium Ethylenediamine Tetraacetate (EDTA); 31 mmol/L Sodium Azide; Adjusted to neutral pH of 7.2
- Collection tubes can be a chambered
collection tube 26, as shown inFIGS. 1 , 6 a, 6 b, and 6 c, orindividual collection tubes 126, as shown inFIGS. 8 and 9 . -
Chambered collection tube 26 is shown in different views inFIGS. 6 a, 6 b, 6 c. Collection tubes fit over the end of the pad compression tube and have one or more chambers for receiving and holding collected samples. These chambers or compartments are separated allowing samples to remain distinct and free from contamination. In any embodiment, collection tube, at 26 inFIG. 1 and at 126 inFIGS. 8 and 9 , when inserted on end of pad compression tube, 20 inFIG. 1 , 120 inFIG. 8 , and 150 inFIG. 9 is in fluid communication with pad compression tube. Collection tube, at 26 inFIG. 1 and at 126 inFIGS. 8 and 9 , can be provided with a tube cap, at 28 inFIG. 1 , and at 128 inFIGS. 8 and 9 , sealing the tubes. - Eppendorf-
type collection tubes 126, inFIGS. 8 and 9 , collect the separate and distinct saliva samples once they pass through a pad compression tube. Eppendorf-type collection tubes 126 are conical at their closed end, round at the open end, and comprised offlexible lids 128 that remain attached to thetube 126 whether open or closed. The Eppendorf-type collection tubes 126 may be attached together on the outside surface. The Eppendorf-type collection tubes 126 remain inwardly distinct in that each receives one of the distinct and separate saliva samples and said samples remain separate and distinct once in the Eppendorf-type collection tubes 126. The Eppendorf-typecollection tube lid 128 is then closed, retaining the fluid sample's integrity and quantity. - Handles, pad compression tubes, and collection tube can be made using any number of different processes familiar to those with skill in the art, such as by injection molding, compression molding, casting; incorporating materials such as thermoplastics, thermosets, glass, metal, etc. The light pipe indicator window can be made of clear material-glass, plastic, Perspex; sample sufficiency indicator changes color or when something is moved, i.e., changes condition.
- In the preferred embodiment, handle is made of two elongated pieces of General Purpose Styrene which fit together over a portion of the absorbent pad. See
FIG. 10 . Handle is preferably made of two pin and ultrasonically assembled halves. Those of skill in the art know that the handle can be made of any one of numerous materials. - In the preferred embodiment collecting saliva, though other embodiments for collecting samples other than saliva exist (such as collection of water for environmental testing purposes, urine analysis for drug testing, bioavailability testing in the pharmaceutical industry and many others), absorbent pad is placed in the mouth under the tongue. Absorbent pad expands when a specimen sample is received. When indicator indicates sufficient sample has been obtained, Indicator provides a visual indication of the same.
- In order to enrich the specimen with immunoglobulins, which are present under the lip line at the end of the collection process, the specimen sample collection device is taken and “swabbed” once across the gums from one side to the other, then reversed and swabbed across the gum line a second time in the opposite direction.
- In order to collect saliva, the specimen sample collection device is placed under the tongue and allowed to remain there until the visual indicator in the device—a light pipe showing a blue coloration—disappears completely. The typical collection time for sample adequacy is in the range of 1-2 minutes. The disappearance of the visual indicator may be observed by a second person or in the event of the sample being collected in the privacy of the home, by a donor in isolation The device may be removed from the mouth to visually inspect for the disappearance of the color and replaced under the tongue immediately without detriment to the collection or subsequent test procedure.
- In operation using a split
absorbent pad 115 and a dual outlet dual channel pad compression tube 120, the user places thepad 115 into the dual outletpad compression tube 115 with the split end facing downwards, and places the Eppendorf-type collection tube 126 on theoutlets 122 of the dual outlet pad compression tube 120, and pushes onhandle 114, forcing thepad 115 all the way down to the bottom of the compression tube 120 until the end of thehandle 114 can be pushed no closer to the bottom of the compression tube 120. Pushing expels specimen from splitabsorbent pad 115, which then travels in fluid communication through the dual outlet pad compression tube 120, through theoutlets 122 and intocollection tubes 126. Thecollection tubes 126 thus provide samples for supplemental or confirmatory testing as well as for independent storage or transportation. Two samples are thus provided. Depending upon the dimensions and type of pad material used the individual forks of the absorbent material will release between 0.3 ml and 2 ml of pure saliva. In instances where the individual samples, are to be transported to a laboratory or remote location, or are not for immediate testing, a preservative buffer may be introduced either in the compression tube or the collection receptacles to maintain the integrity of the sample so collected. The buffer may be a liquid or dry buffer. In instances where the samples are to be tested immediately, or at the point-of-care, the device may be supplied without buffer. In order to determine the volume of specimen received by this action, graduated tubes, such as small Eppendorf tubes, available “off the shelf” from a number of vendors, may be used. Alternatively, where no duplicate sampling is required, the collection tube can be a single channel collection receptacle or Eppendorf tube. Depending upon sampling requirements alternative customized collection tubes may be adapted for use with the invention. Each of the tubes used in connection with the collection tool are fitted with individual caps for sealing purposes. These caps may be tamper-proof for evidentiary purposes. Similarly, the pad compression tube can be provided with a cap or caps for sealing. - The specimen
sample collection device 10 can be provided with one or more lateralflow test strips handle 14 in fluid communication with theabsorbent pad 15 by one ormore membranes - The test strip is coated or “striped” with one or more analyte of interest, together with a control material usually Protein A-gold coated to human IgG to verify that the test strip is working appropriately. Such strips are now very commonly available and well characterized. After a short period of time (which may vary from 2 to 20 minutes), a Control Line will appear on the test strip, and in instances of a positive specimen a second line (the Test Line) will appear indicating positivity for the analyte of interest.
- The test strip is comprised of reagents that test qualitatively (for the presence or absence of analytes or substances) and/or semi-quantitatively (providing an estimate of the quantity) of the chemical(s)/substances for which the device tests within the fluid sample. In the preferred embodiment the test strip is located in the collector handle housing, above the attachment loci of the absorbent pad. The collector handle housing has a window-type opening above a portion of the test strip through which results from the test strip can be viewed.
- A reagent test strip comprised of at least one reagent chemical that upon contact with the chemical for which it tests or a by-product of the chemical for which it tests in the testing fluid, undergoes a chemical reaction which produces or activates an indicator, preferably visual, of the presence or absence and/or quantity of the chemical for which it tests.
- The test system may be applied to a number of different diseases, and analytical tests, which includes HIV, drugs of abuse, bacteria, viruses, environmental toxins and others. Reaction times and run times will vary depending upon the characteristics of individual test strips, which are optimized to achieved maximum sensitivity and specificity. The characteristics of each individual test will be defined in the respective package insert for the products, however, as an example, an HIV test optimized for oral fluid detection using the specimen sample collection device will provide results within a period of 10-20 minutes with a sensitivity greater than 95% and a specificity of greater than 99%. What should be understood in the case of an HIV test is that the appearance of a Test Line in the presence of a Control Line is indicative of an initially positive or non-negative result.
- When more than one test strip is provided they are arranged side-by-side on the
handle 14, as shown inFIGS. 4 and 10 , at 16 a, 16 b. In this embodiment, saliva collected in identical fashion to the embodiments described above, is transferred to two test strips instead of one by two membranes, 17 a, 17 b. Using this configuration, a multiplicity of analytes, for instance drugs of abuse, including but not limited to the NIDA-5 series of drugs, benzodiazepines, Oxycodone, and others, as well as therapeutic drugs and multiple infectious diseases for instance may be detected simultaneously using a single oral fluid collection device and test system. Test strips for the NIDA-5 series of drugs have been optimized in the specimen sample collection device to run within 15 minutes from the time sample adequacy has been achieved. - In this embodiment, the
reagent test strips 16 are located in the collector handle 14 housing with a window-type opening 60 above eachtest strip 16, or, alternatively, a single window-type opening above all the test strips. Each test strip contains a reagent test for analyzing the qualitative (presence or absence) and/or quantitative data of the chemical for which it tests within the fluid sample. One of skill in the art would understand that each test strip may test for a different chemical or the same chemical as any other test strip. In the preferred embodiment, the test strips extend linearly down the length of the collector handle housing, parallel to one another. In another embodiment, the test strips may be adjacent to one, two or more additional test strips. - In embodiments including a
test strip 16 under atest strip opening 60, the results may be read visually or may be read by electronic reading devices including pocket-PC devices, PDAs and others. In the preferred embodiment of this invention a pocket-PC driven system, utilizes proprietary software to digitally record images from the lateral flow test strips. The reader combines a “Pocket PC” (PDA-sized) reading system, printing device, camera and software, capable of reading multiple lines within a pre-set reading window. Once the specimen sample collection device incorporating one or more test strips has run and the immunochromatographic test results have been observed visually, (after the pre-established reaction time is over), a plastic cap is placed over the absorbent collection pad of the specimen sample collection device, if desired, then the opposite end of the device (handle-first) is inserted into the port of the hand-held reading device. The reading device initially does a diagnostic “self test” to ensure that the reader is working appropriately then performs a read out of the intensity of the coloration of the individual line (or lines) on the test strip (or strips). The results of this are fed automatically to a printing device, which prints out a permanent record of the results for each drug or other analyte being tested. The visual appearance of a line, or the confirmation of a line in the case of drug tests using the hand-held reading system is an indication that the test is negative or non-positive for that particular analyte or drug. This is the opposite of what one would find for similar tests for HIV and other analytes where the presence of a Test Line in the presence of a Control Line is indicative of a positive or non-negative result. The invention provides visually read, qualitative results, which may be quantitated using available electronic, digital or other format readers. These in turn may be either small, PDA-sized (hand-held) systems or portable and non portable instruments that utilize electromagnetic radiation, chemiluminescence, digital photography and other techniques, while providing a digital printout of the quantitative results obtained. - Fluid forced through separate porous filters in pad compression tube and into mutually distinct gradiated Eppendorf-type tubes attached to the pad compression tube outlets. Each Eppendorf tube is then bar coded. A bar code may further be provided on the specimen sample collection device handle. A recess is molded into the specimen sample collection device handle and the bar code is imprinted thereon.
- Those skilled in the art will recognize that numerous modifications and changes may be made to the preferred embodiment without departing from the scope of the claimed invention. It will, of course, be understood that modifications of the invention, in its various aspects, will be apparent to those skilled in the art, some being apparent only after study, others being matters of routine mechanical, chemical and electronic design. No single feature, function or property of the preferred embodiment is essential. Other embodiments are possible, their specific designs depending upon the particular application. As such, the scope of the invention should not be limited by the particular embodiments herein described but should be defined only by the appended claims and equivalents thereof.
Claims (19)
1. A specimen sample collection device and test system, comprising:
a handle having a sufficiency indicator;
an absorbent pad partially contained within said handle;
a pad compression tube insertable over said absorbent pad and around an end of said handle, said pad compression tube defining one or more pad compression tube chambers; and,
a collection tube having one or more sample chambers, said collection tube attachable to said pad compression tube, and wherein when said collection tube is attached to said pad compression tube each of said one or more chambers of said collection tube is in fluid communication with at least one of said one or more pad compression tube chambers, and further wherein said collection tube is detachable from said pad compression tube and sealable.
2. The apparatus of claim 1 , wherein said indicator is a light pipe having a first end surface with a marking; a second surface in physical contact with said absorbent pad creating a refractive boundary, wherein said second surface is oriented at an angle of incidence to said first surface such that when the absorbent pad absorbs a sufficient liquid sample the refractive properties of said boundary alter the observability of the mark.
3. The apparatus of claim 1 , wherein said indicator comprises a window, a sponge and a loaded spring set into said sponge, wherein said sponge is in fluid communication with the absorbent pad, such that when the sponge is softened by absorption of liquid the spring partially or completely disengages from sponge and snaps into view of said window, providing visual and audible indication that sample volume is adequate.
4. The apparatus of claim 1 , wherein said indicator comprises a clear window and a material which expands when wetted, said material in fluid communication with said absorbent pad, wherein the expandable material will expand to obscure the window when sample volume is adequate.
5. The apparatus of claim 1 , wherein said indicator comprises an electrical circuit, said electrical circuit comprising:
a pair of leads composed of galvanically dissimilar conductors connected across said absorbent pad, at a location along the absorbent pad selected to indicate sufficient liquid sample has been absorbed, and
a liquid crystal display connected in series between said pair of leads;
such that, when liquid saturates the absorbent pad up to said location, a galvanic couple is created between said pair of leads, allowing electric current to flow through said liquid crystal display and change the liquid crystal display state, thereby providing visual indication of sample adequacy.
6. The apparatus of claim 1 , wherein said indicator comprises a window and a paper with a colored dot located on the inward surface of said paper, wherein said paper becomes translucent when saturated with liquid, and further wherein said paper is located in close proximity to said absorbent pad at a location along the length of said absorbent pad, such that when the absorbent pad becomes saturated with liquid at least to said location the absorbent pad expands to contact the paper, thereby transferring liquid to the paper allowing the paper to become saturated and thereby making the dot visible through said window.
7. The apparatus of claim 1 , wherein the indicator is a window coated on the inside with a hydrochromic material such that when absorbent pad swells with sample it absorbs, the wet, swollen pad touches the inside of the window, reacting with the coating and causing a color change or graphic symbol to appear.
8. The specimen sample collection device of claim 1 , wherein said absorbent pad is split, divided into two parts and connected at a base of said absorbent pad.
9. The specimen sample collection device and test system of claim 1 , wherein said pad compression tube is provided with two chambers into which a split absorbent pad can be placed and each chamber has an outlet.
10. The specimen sample collection device and test system of claim 9 , wherein said collection tubes mate to outlets on said pad compression tube.
11. The specimen sample collection device of claim 1 , wherein said handle is further provided with a bar code number uniquely identifying said handle.
12. The specimen sample collection device and test system of claim 1 , further comprising an electro-optical reader.
13. The specimen sample collection device and test system of claim 1 , wherein said handle is further provided with a ridged lock and said pad compression tube is provided with a depressed key to lock the handle into the pad compression tube.
14. The apparatus of claim 1 , wherein the absorbent pad is folded over upon itself.
15. The specimen sample collection device of claim 1 , further comprising:
a single analyte test strip in said handle, and
a membrane in said handle;
wherein said absorbent pad is in fluid communication with said test strip through said membrane.
16. The specimen sample collection device of claim 1 , further comprising:
two or more analyte test strips in said handle, and
a plurality of membranes in said handle corresponding to said two or more test strips,
wherein said absorbent pad is in fluid communication with each of said test strips through said corresponding membranes.
17. The specimen sample collection device of claim 1 , further comprising:
a plurality of analyte test strips in said handle, and
a single membrane in said handle,
wherein said absorbent pad is in fluid communication with each of said test strips through said membrane.
18. The specimen sample collection device of claim 1 , wherein said absorbent pad is split, divided into two parts and connected at a base of said absorbent pad.
19. A liquid specimen collection device, comprising:
a handle including a sample volume sufficiency indicator within said handle, and further including viewing means for viewing immediate test results from a collected liquid specimen;
absorbent means for collecting a liquid specimen, said absorbent means partially contained within said handle and in fluid communication with said sufficiency indicator
one or more test strips including indication means contained within said handle for providing immediate test results for said collected specimen, said one or more test strips in fluid communication with said absorbent means, and said indication means of said test strips visible to an operator through said viewing means;
means for separating said liquid specimen from said absorbent means into two or more liquid samples;
means for retaining said two or more liquid samples for later analyses.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/411,009 US20090181451A1 (en) | 2004-01-28 | 2009-03-25 | Specimen sample collection device and test system |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53992904P | 2004-01-28 | 2004-01-28 | |
US63061304P | 2004-11-23 | 2004-11-23 | |
US11/045,180 US7618591B2 (en) | 2004-01-28 | 2005-01-27 | Specimen sample collection device and test system |
US12/411,009 US20090181451A1 (en) | 2004-01-28 | 2009-03-25 | Specimen sample collection device and test system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/045,180 Continuation US7618591B2 (en) | 2004-01-28 | 2005-01-27 | Specimen sample collection device and test system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090181451A1 true US20090181451A1 (en) | 2009-07-16 |
Family
ID=34830495
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/045,180 Expired - Fee Related US7618591B2 (en) | 2004-01-28 | 2005-01-27 | Specimen sample collection device and test system |
US12/411,009 Abandoned US20090181451A1 (en) | 2004-01-28 | 2009-03-25 | Specimen sample collection device and test system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/045,180 Expired - Fee Related US7618591B2 (en) | 2004-01-28 | 2005-01-27 | Specimen sample collection device and test system |
Country Status (5)
Country | Link |
---|---|
US (2) | US7618591B2 (en) |
EP (1) | EP1718410B1 (en) |
CA (1) | CA2554713C (en) |
MX (1) | MXPA06008646A (en) |
WO (1) | WO2005072398A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012174A1 (en) * | 2010-07-19 | 2012-01-26 | Andalyze, Inc. | Sensor housing and reagent chemistry |
CN102946803A (en) * | 2010-06-24 | 2013-02-27 | 伊莱克有限公司 | Blood collection module for measuring alcohol concentration |
DE102013000901A1 (en) * | 2013-01-18 | 2014-07-24 | Dräger Safety AG & Co. KGaA | Device for receiving and dispensing saliva |
US8815156B2 (en) | 2010-07-19 | 2014-08-26 | Andalyze, Inc. | Sensor housing and reagent chemistry |
CN104083181A (en) * | 2014-07-30 | 2014-10-08 | 鲁笑钦 | Independent vaginal secretion sampling detection and diagnosis equipment |
US8951472B2 (en) | 2010-07-19 | 2015-02-10 | Andalyze, Inc. | Portable fluorimetric apparatus, method and system |
US20160024559A1 (en) * | 2014-07-24 | 2016-01-28 | The Bode Technology Group, Inc. | Specimen collection with reagent lined collectors |
US20160077091A1 (en) * | 2013-04-26 | 2016-03-17 | Express Diagnostics International, Inc. | Portable testing system for detecting selected drugs or compounds in noncontrolled environments |
CN105451665A (en) * | 2013-11-06 | 2016-03-30 | 奥林巴斯株式会社 | Body-fluid sampling device |
US20160123856A1 (en) * | 2013-06-12 | 2016-05-05 | Oasis Diagnostics Corporation | Rna/prtein/dna preferential fluid sample collection system and methods |
EP3165173A1 (en) * | 2015-11-04 | 2017-05-10 | Moishe Bodner | Splittable fluid sample collector |
WO2018085858A1 (en) * | 2016-11-07 | 2018-05-11 | The Climate Corporation | Agricultural implements for soil and vegetation analysis |
US10035146B2 (en) | 2013-05-24 | 2018-07-31 | Premier Biotech, Inc. | Multi-stage oral-fluid testing device |
WO2020146826A1 (en) * | 2019-01-10 | 2020-07-16 | Confirm Biosciences, Inc. | Device & method for saliva-based analyte testing |
US10980520B2 (en) | 2015-10-19 | 2021-04-20 | Green Panther, LLC | Urine sampling vessel |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9811818B1 (en) * | 2002-10-01 | 2017-11-07 | World Award Academy, World Award Foundation, Amobilepay, Inc. | Wearable personal digital device for facilitating mobile device payments and personal use |
CA2554713C (en) * | 2004-01-28 | 2011-11-01 | Bamburgh Marrsh Llc | Specimen sample collection device and test system |
US8025851B2 (en) * | 2008-04-07 | 2011-09-27 | Bamburgh Marrsh Llc | Specimen sample collection device and test system |
US7927548B2 (en) * | 2005-01-27 | 2011-04-19 | Bamburgh Marsh Llc | Specimen sample collection device and test system |
US8049165B2 (en) * | 2006-02-24 | 2011-11-01 | Coventry Diagnostics LLC | Saliva assay technique for heavy metal |
GB2435832A (en) * | 2006-03-03 | 2007-09-12 | Ethicon Inc | Sample Collection and Testing Device with Swing Arm |
US8122174B2 (en) * | 2006-03-31 | 2012-02-21 | Research In Motion Limited | System and method for provisioning a remote resource for an electronic device |
US20070282181A1 (en) * | 2006-06-01 | 2007-12-06 | Carol Findlay | Visual medical sensor indicator |
US7901623B2 (en) * | 2006-09-26 | 2011-03-08 | Lawrence Livermore National Security, Llc | Lateral flow strip assay |
US8827945B2 (en) | 2006-11-06 | 2014-09-09 | Aardvark Medical, Inc. | Irrigation and aspiration devices and methods |
MY157276A (en) * | 2007-02-12 | 2016-05-31 | Porex Corp | Porous barrier media comprising color change indicators |
DE102007020895B3 (en) * | 2007-05-04 | 2008-08-07 | Dräger Safety AG & Co. KGaA | Liquid sample i.e. saliva, receiving device for use by physician, has sample carrier ejector manually and axially adjustable within sample carrier holder at grip region, such that sample carrier is detachable from holder by ejector |
JP4865664B2 (en) * | 2007-09-28 | 2012-02-01 | 富士フイルム株式会社 | Method of mixing two or more liquids in a porous carrier |
GB0723273D0 (en) * | 2007-11-28 | 2008-01-09 | Surescreen Diagnostics Ltd | Oral fluid collector |
US20090143699A1 (en) * | 2007-11-29 | 2009-06-04 | John Wu | Fluid sample collecting and analyzing apparatus |
GB0725234D0 (en) * | 2007-12-24 | 2008-02-06 | Oxtex Ltd | Electrochemical assays |
CA2943923C (en) * | 2008-04-29 | 2018-02-06 | Psychemedics Corporation | Solid phase multi-analyte assay |
US8084215B2 (en) * | 2008-04-29 | 2011-12-27 | Psychemedics Corporation | Non-proteolytic method for the determination of analytes in keratinized structures |
US8770049B2 (en) * | 2008-07-04 | 2014-07-08 | Koninklijke Philips N.V. | Sampling device and sampling method |
WO2010055460A1 (en) | 2008-11-17 | 2010-05-20 | Koninklijke Philips Electronics N.V. | A device for collecting a biological fluid sample |
US8105549B2 (en) * | 2008-11-19 | 2012-01-31 | Sun Biomedical Laboratories, Inc | Sample collection device |
DE102009010563A1 (en) | 2009-02-16 | 2010-08-26 | Matthias W. Engel | Device for the detection of analytes in body fluids |
EP2230503B1 (en) * | 2009-03-16 | 2013-08-14 | Dutch Space B.V. | Sample preparation system, swab unit and base station therefore |
US9198641B2 (en) * | 2009-04-07 | 2015-12-01 | Oasis Diagnostics, Corporation | Specimen sample collection system |
KR101123771B1 (en) * | 2010-07-29 | 2012-03-16 | 주식회사 디에이텍 | Apparatus for measuring a blood alcohol concentration |
JP6012052B2 (en) * | 2010-10-01 | 2016-10-25 | ホロジック, インコーポレイテッドHologic, Inc. | Immunoassay test strips for use in diagnostic systems |
PT105553B (en) * | 2011-03-01 | 2020-04-20 | Infogene Lda | PORTABLE DEVICE FOR THE STORAGE, TRANSPORT AND RECOVERY OF BIOLOGICAL MATERIAL |
US9529002B2 (en) * | 2011-05-18 | 2016-12-27 | Balwant Rai | Biomarkers for prediction, diagnosis, and monitoring of Alzheimer's disease |
US9927445B2 (en) * | 2011-05-18 | 2018-03-27 | Balwant Rai | Biomarkers for prediction, diagnosis, and monitoring of parkinson's disease |
EP2721103A1 (en) | 2011-06-15 | 2014-04-23 | Porex Corporation | Sintered porous plastic liquid barrier media and applications thereof |
US9121827B2 (en) | 2011-06-30 | 2015-09-01 | Mocon, Inc. | Method of contemporaneously monitoring changes in analyte concentration in a plurality of samples on individual schedules |
EP3255435A1 (en) | 2012-04-13 | 2017-12-13 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
US20160003819A1 (en) * | 2012-09-12 | 2016-01-07 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
US20140072959A1 (en) * | 2012-09-12 | 2014-03-13 | Force Diagnostics, Inc. | Rapid tests for insurance underwriting |
US11020032B2 (en) | 2013-03-15 | 2021-06-01 | Lars Otto LIEPOLD | Fluid sampling apparatus and method |
CA2922536C (en) | 2013-08-28 | 2022-05-03 | Psychemedics Corporation | Integrity testing of hair samples |
WO2015059686A1 (en) * | 2013-10-22 | 2015-04-30 | Ilex Medical Ltd. | Kit and method for collecting body fluid for medical diagnosis |
US9851348B2 (en) * | 2014-03-12 | 2017-12-26 | American Bio Medica Corporation | System and method for lateral flow immunoassay testing |
US10287618B2 (en) * | 2014-03-28 | 2019-05-14 | 3M Innovative Properties Company | Wash monitor composition, device, and method of use |
US20170102382A1 (en) * | 2014-07-25 | 2017-04-13 | Becton, Dickinson And Company | Analyte test strip assays, and test strips and kits for use in practicing the same |
EP3792629A1 (en) * | 2015-02-17 | 2021-03-17 | Bio-Marketing-T, Ltd. (BMT) | Devices for biological sample collection and analysis and methods of use thereof |
MX2017013898A (en) * | 2015-04-30 | 2018-08-15 | Wellmetris Llc | Sample collection device and method for urine and other fluids. |
ITUB20153258A1 (en) * | 2015-08-27 | 2017-02-27 | Copan Italia Spa | Device for the collection, transfer and storage of biological and / or chemical material samples |
GB201519565D0 (en) * | 2015-11-05 | 2015-12-23 | Alere San Diego Inc | Sample preparation device |
GB201703383D0 (en) | 2017-03-02 | 2017-04-19 | Gargle Tech Ltd | Testing for particulates |
US10660619B2 (en) | 2017-07-19 | 2020-05-26 | Evanostics Llc | Cartridges for oral fluid analysis and methods of use |
EP3724636A4 (en) | 2017-12-15 | 2021-08-18 | Evanostics, LLC | OPTICAL READER FOR ANALYTE CHECK |
US20200390426A1 (en) * | 2017-12-22 | 2020-12-17 | Aobiome Llc | Devices and methods for microbiome sampling |
US11680877B2 (en) | 2018-09-05 | 2023-06-20 | Hero Scientific Ltd. | Testing for particulates |
US12066383B2 (en) | 2018-12-18 | 2024-08-20 | Aspida Dx Inc. | Optical analyte detection |
US10422729B1 (en) | 2019-03-08 | 2019-09-24 | Biodesix, Inc. | Blood sample separation devices and methods |
KR102325441B1 (en) * | 2019-11-15 | 2021-11-10 | 이형기 | Roll sheet type sampling kit |
US20210378639A1 (en) * | 2020-06-04 | 2021-12-09 | T. Que COLLINS | Method for detecting antigens or antibodies to the antigens using EBC and EBC collection device |
AU2021317741A1 (en) * | 2020-07-13 | 2023-03-09 | Asap Breatheassist Pty Ltd | Sample collection device, sample collection kit, sample collection system, diagnostic device, and associated methods |
ES2895200A1 (en) * | 2020-08-17 | 2022-02-17 | Sant Joan De Deu Hospital | Device and procedure for detecting pathogens in a sample (Machine-translation by Google Translate, not legally binding) |
EP4203802B1 (en) | 2020-08-28 | 2024-02-14 | Porex Corporation | Liquid collection device |
WO2022146624A1 (en) * | 2020-12-29 | 2022-07-07 | Cal Poly Corporation | Metered liquid sample collection device |
CA3202405A1 (en) | 2021-01-06 | 2022-07-14 | Zvi Feldman | Filtration sampling devices |
US20220249073A1 (en) * | 2021-02-08 | 2022-08-11 | Orthogonal Diagnostics, Inc. | Integrated sample collection and test device |
US11845082B1 (en) * | 2021-03-25 | 2023-12-19 | Amazon Technologies, Inc. | Specimen tube |
SE545594C2 (en) * | 2021-06-18 | 2023-11-07 | Arta Plast Ab | Sample collection device for retrieval of a fluid sample |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931051A (en) * | 1987-02-06 | 1990-06-05 | Edge Enterprises, Inc. | Wetness indicator |
US5016982A (en) * | 1986-07-22 | 1991-05-21 | Raychem Corporation | Liquid crystal display having a capacitor for overvoltage protection |
US5393496A (en) * | 1990-12-18 | 1995-02-28 | Saliva Diagnostic Systems, Inc. | Saliva sampling device and sample adequacy system |
USD369664S (en) * | 1993-09-16 | 1996-05-07 | The Kendall Company | Connector for device for applying compressive pressure to the leg |
USD411014S (en) * | 1997-12-05 | 1999-06-15 | Bayer Corporation | Container for reagent |
US6365417B1 (en) * | 2000-02-09 | 2002-04-02 | A-Fem Medical Corporation | Collection device for lateral flow chromatography |
US6372516B1 (en) * | 2000-09-07 | 2002-04-16 | Sun Biomedical Laboratories, Inc. | Lateral flow test device |
US6451619B1 (en) * | 1994-06-29 | 2002-09-17 | Inverness Medical Switzerland Gmbh | Monitoring methods and devices for use therein |
US20030113906A1 (en) * | 2001-12-14 | 2003-06-19 | Sangha Jangbir S. | Method and apparatus for DNA collection |
US20080118397A1 (en) * | 2005-01-27 | 2008-05-22 | Slowey Paul D | Specimen sample collection device and test system |
US7618591B2 (en) * | 2004-01-28 | 2009-11-17 | Bamburgh Marrsh Llc | Specimen sample collection device and test system |
US20090306543A1 (en) * | 2008-04-07 | 2009-12-10 | Bamburgh Marrsh Llc | Specimen Sample Collection Device and Test System |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4286210A (en) * | 1979-08-16 | 1981-08-25 | Vladimir Ignatjev | Air ion and charge detector |
US4387725A (en) * | 1981-02-10 | 1983-06-14 | Mull John D | Device for use in the collection and transportation of medical specimens |
US4353868A (en) * | 1981-05-29 | 1982-10-12 | Sherwood Medical Industries Inc. | Specimen collecting device |
US4444193A (en) * | 1982-01-11 | 1984-04-24 | Medtronic, Inc. | Fluid absorbent quantitative test device |
US4999285A (en) * | 1984-11-15 | 1991-03-12 | Syntex (U.S.A.) Inc. | Chromatographic cassette |
DE3856421T2 (en) * | 1987-04-27 | 2000-12-14 | Unilever Nv | Specific binding test procedures |
US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US4895808A (en) | 1988-07-26 | 1990-01-23 | Romer Labs, Inc. | Method and apparatus for adsorption detection |
US5103836A (en) * | 1990-02-28 | 1992-04-14 | Epitope, Inc. | Oral collection device and kit for immunoassay |
US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
US5238652A (en) * | 1990-06-20 | 1993-08-24 | Drug Screening Systems, Inc. | Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques |
US5268148A (en) | 1990-12-18 | 1993-12-07 | Saliva Diagnostic Systems, Inc. | Saliva sampling device and sample adequacy system |
US5283038A (en) | 1990-12-18 | 1994-02-01 | Saliva Diagnostic Systems, Inc. | Fluid sampling and testing device |
US5376337A (en) | 1990-12-18 | 1994-12-27 | Seymour; Eugene H. | Saliva sampling device and sample adequacy system |
US5380492A (en) | 1990-12-18 | 1995-01-10 | Seymour; Eugene H. | Sampling device and sample adequacy system |
US5230864A (en) * | 1991-04-10 | 1993-07-27 | Eastman Kodak Company | Gravity assisted collection device |
US5334502A (en) * | 1991-11-27 | 1994-08-02 | Osborn Laboratories, Inc. | Method of collecting, identifying, and quantifying saliva |
US5494646A (en) | 1993-04-14 | 1996-02-27 | Seymour; Eugene H. | Sampling device and sample adequacy system |
US6423550B1 (en) * | 1995-03-30 | 2002-07-23 | Ortho Pharmaceutical Corporation | Home oral fluid sample collection device and package for mailing of such device |
US20010051350A1 (en) * | 1995-05-02 | 2001-12-13 | Albert Nazareth | Diagnostic detection device and method |
US6060502A (en) | 1995-06-05 | 2000-05-09 | Rhone-Poulenc Agrochimie | Pesticidal sulfur compounds |
WO1997003209A1 (en) | 1995-07-12 | 1997-01-30 | Charm Sciences, Inc. | Test apparatus, system and method for the detection of test samples |
US5830154A (en) * | 1996-01-11 | 1998-11-03 | Epitope, Inc. | Device for collecting substances for testing |
US5964543A (en) * | 1996-04-03 | 1999-10-12 | Dai Nippon Printing Co., Ltd. | Roll-shaped image-receiving sheet for thermal transfer printing and process for forming images thereon |
US5910122A (en) * | 1996-06-04 | 1999-06-08 | Americare Health Scan Inc. | Saliva collector with an aspirating pipette |
AU3962397A (en) | 1996-10-01 | 1998-04-24 | Nicholas G. Levandoski | Sample collection, dispensing and retention device |
US5922614A (en) * | 1997-06-04 | 1999-07-13 | Avitar Incorporated | Sample collection method with extraction sleeve |
US6258548B1 (en) * | 1997-06-05 | 2001-07-10 | A-Fem Medical Corporation | Single or multiple analyte semi-quantitative/quantitative rapid diagnostic lateral flow test system for large molecules |
US5962336A (en) | 1997-10-20 | 1999-10-05 | Sun; Ming | Multi-test panel |
DE19748331C1 (en) * | 1997-10-31 | 1999-01-28 | Primed Medizintechnik Gmbh | Appts for saliva sampling |
US6103602A (en) | 1997-12-17 | 2000-08-15 | Advanced Micro Devices, Inc. | Method and system for providing a drain side pocket implant |
US6267722B1 (en) | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6303081B1 (en) * | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
GB2339615B (en) * | 1998-07-14 | 2001-02-07 | Cozart Bioscience Ltd | Screening device and method of screening an immunoassay test |
GB2342443A (en) | 1998-10-02 | 2000-04-12 | Abp Diagnostics Limited | Immunoassay device |
US20010008614A1 (en) * | 1998-11-16 | 2001-07-19 | Jack L. Aronowitz | Sample collection system and method of use thereof |
US6046058A (en) | 1998-11-20 | 2000-04-04 | Sun; Ming | Color-coded test strip |
US6376251B1 (en) * | 1999-02-03 | 2002-04-23 | Medtox Scientific, Inc. | On-site drug testing method |
US6702988B1 (en) * | 1999-04-21 | 2004-03-09 | Peter J. Sagona | Automatic on-site drug testing system and method |
DE19926931A1 (en) * | 1999-06-14 | 2000-12-21 | Roche Diagnostics Gmbh | Method and device for checking the liquid absorption of a test layer of an analysis element |
US6489172B1 (en) | 2000-01-05 | 2002-12-03 | Varian, Inc. | Saliva sampling device |
US6627152B1 (en) | 2000-04-29 | 2003-09-30 | Branan Medical Corp. | Fluid testing apparatus |
US6468474B2 (en) * | 2000-07-06 | 2002-10-22 | Varian, Inc. | Saliva testing and confirmation device |
JP2002072972A (en) | 2000-08-28 | 2002-03-12 | Kawasaki Microelectronics Kk | Lcd driver |
US6440087B1 (en) | 2001-05-25 | 2002-08-27 | Choicepoint Asset Co. | Oral fluid collection device and collection method |
WO2003007814A1 (en) | 2001-07-18 | 2003-01-30 | Agilex Biosciences, Inc. | Device and method for collecting, transporting and recovering low molecular weight analytes in saliva |
US7879293B2 (en) * | 2001-09-28 | 2011-02-01 | Orasure Technologies, Inc. | Sample collector and test device |
US7758744B2 (en) * | 2001-10-05 | 2010-07-20 | Stephen Eliot Zweig | Dual glucose-turbidimetric analytical sensors |
US6634243B1 (en) * | 2002-01-14 | 2003-10-21 | Rapid Medical Diagnostics Corporation | Sample testing device |
US6841159B2 (en) * | 2002-01-30 | 2005-01-11 | The United States Of America As Represented By The Secretary Of The Navy | Rapid lateral flow assay for determining exposure to Mycobacterium tuberculosis and other mycobacteria |
US7560239B2 (en) * | 2002-06-04 | 2009-07-14 | Lin-Zhi International Inc. | Homogeneous enzyme immunoassay for simultaneous detection of multiple analytes |
GB2391813B (en) * | 2002-08-14 | 2006-03-29 | Cozart Bioscience Ltd | An oral fluid collection, transfer and transportation device and method |
-
2005
- 2005-01-27 CA CA2554713A patent/CA2554713C/en not_active Expired - Fee Related
- 2005-01-27 WO PCT/US2005/002684 patent/WO2005072398A2/en active Search and Examination
- 2005-01-27 EP EP05712214A patent/EP1718410B1/en not_active Expired - Lifetime
- 2005-01-27 MX MXPA06008646A patent/MXPA06008646A/en active IP Right Grant
- 2005-01-27 US US11/045,180 patent/US7618591B2/en not_active Expired - Fee Related
-
2009
- 2009-03-25 US US12/411,009 patent/US20090181451A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5016982A (en) * | 1986-07-22 | 1991-05-21 | Raychem Corporation | Liquid crystal display having a capacitor for overvoltage protection |
US4931051A (en) * | 1987-02-06 | 1990-06-05 | Edge Enterprises, Inc. | Wetness indicator |
US5393496A (en) * | 1990-12-18 | 1995-02-28 | Saliva Diagnostic Systems, Inc. | Saliva sampling device and sample adequacy system |
USD369664S (en) * | 1993-09-16 | 1996-05-07 | The Kendall Company | Connector for device for applying compressive pressure to the leg |
US6451619B1 (en) * | 1994-06-29 | 2002-09-17 | Inverness Medical Switzerland Gmbh | Monitoring methods and devices for use therein |
USD411014S (en) * | 1997-12-05 | 1999-06-15 | Bayer Corporation | Container for reagent |
US6365417B1 (en) * | 2000-02-09 | 2002-04-02 | A-Fem Medical Corporation | Collection device for lateral flow chromatography |
US6372516B1 (en) * | 2000-09-07 | 2002-04-16 | Sun Biomedical Laboratories, Inc. | Lateral flow test device |
US20030113906A1 (en) * | 2001-12-14 | 2003-06-19 | Sangha Jangbir S. | Method and apparatus for DNA collection |
US7618591B2 (en) * | 2004-01-28 | 2009-11-17 | Bamburgh Marrsh Llc | Specimen sample collection device and test system |
US20080118397A1 (en) * | 2005-01-27 | 2008-05-22 | Slowey Paul D | Specimen sample collection device and test system |
US20090306543A1 (en) * | 2008-04-07 | 2009-12-10 | Bamburgh Marrsh Llc | Specimen Sample Collection Device and Test System |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102946803A (en) * | 2010-06-24 | 2013-02-27 | 伊莱克有限公司 | Blood collection module for measuring alcohol concentration |
US8951472B2 (en) | 2010-07-19 | 2015-02-10 | Andalyze, Inc. | Portable fluorimetric apparatus, method and system |
US8815156B2 (en) | 2010-07-19 | 2014-08-26 | Andalyze, Inc. | Sensor housing and reagent chemistry |
WO2012012174A1 (en) * | 2010-07-19 | 2012-01-26 | Andalyze, Inc. | Sensor housing and reagent chemistry |
DE102013000901A1 (en) * | 2013-01-18 | 2014-07-24 | Dräger Safety AG & Co. KGaA | Device for receiving and dispensing saliva |
DE102013000901B4 (en) * | 2013-01-18 | 2014-09-25 | Dräger Safety AG & Co. KGaA | Device for receiving and dispensing saliva |
AU2014200325B2 (en) * | 2013-01-18 | 2016-05-19 | Draeger Safety Ag & Co Kgaa | Device for collecting and releasing saliva |
US20160077091A1 (en) * | 2013-04-26 | 2016-03-17 | Express Diagnostics International, Inc. | Portable testing system for detecting selected drugs or compounds in noncontrolled environments |
US20200009550A1 (en) * | 2013-05-24 | 2020-01-09 | Premier Biotech, Inc. | Multi-stage oral-fluid testing device |
US11090648B2 (en) * | 2013-05-24 | 2021-08-17 | Premier Biotech, Inc. | Multi-stage oral-fluid testing device |
US10035146B2 (en) | 2013-05-24 | 2018-07-31 | Premier Biotech, Inc. | Multi-stage oral-fluid testing device |
US20220023858A1 (en) * | 2013-05-24 | 2022-01-27 | Premier Biotech, Inc. | Multi-stage oral-fluid testing device |
US12214345B2 (en) * | 2013-05-24 | 2025-02-04 | Premier Biotech, Llc | Multi-stage oral-fluid testing device with cap containing plunger for oral-fluid release from collection sponge |
US20160123856A1 (en) * | 2013-06-12 | 2016-05-05 | Oasis Diagnostics Corporation | Rna/prtein/dna preferential fluid sample collection system and methods |
EP3066986A4 (en) * | 2013-11-06 | 2017-08-02 | Olympus Corporation | Body-fluid sampling device |
US20160174948A1 (en) * | 2013-11-06 | 2016-06-23 | Olympus Corporation | Body fluid collection device |
CN105451665A (en) * | 2013-11-06 | 2016-03-30 | 奥林巴斯株式会社 | Body-fluid sampling device |
US20160024559A1 (en) * | 2014-07-24 | 2016-01-28 | The Bode Technology Group, Inc. | Specimen collection with reagent lined collectors |
CN104083181A (en) * | 2014-07-30 | 2014-10-08 | 鲁笑钦 | Independent vaginal secretion sampling detection and diagnosis equipment |
US10980520B2 (en) | 2015-10-19 | 2021-04-20 | Green Panther, LLC | Urine sampling vessel |
CN106618642A (en) * | 2015-11-04 | 2017-05-10 | 莫伊舍·博德纳 | Detachable Fluid Sample Collector |
US10722883B2 (en) | 2015-11-04 | 2020-07-28 | Moishe Bodner | Splittable fluid sample collector |
US10105699B2 (en) | 2015-11-04 | 2018-10-23 | Moishe Bodner | Splittable fluid sample collector |
EP3165173A1 (en) * | 2015-11-04 | 2017-05-10 | Moishe Bodner | Splittable fluid sample collector |
WO2018085858A1 (en) * | 2016-11-07 | 2018-05-11 | The Climate Corporation | Agricultural implements for soil and vegetation analysis |
US11871691B2 (en) | 2016-11-07 | 2024-01-16 | Climate Llc | Agricultural implements for soil and vegetation analysis |
WO2020146826A1 (en) * | 2019-01-10 | 2020-07-16 | Confirm Biosciences, Inc. | Device & method for saliva-based analyte testing |
US20220117588A1 (en) * | 2019-01-10 | 2022-04-21 | Confirm Biosciences, Inc. | Device & method for saliva-based analyte testing |
Also Published As
Publication number | Publication date |
---|---|
US7618591B2 (en) | 2009-11-17 |
EP1718410A2 (en) | 2006-11-08 |
CA2554713C (en) | 2011-11-01 |
CA2554713A1 (en) | 2005-08-11 |
MXPA06008646A (en) | 2008-02-13 |
WO2005072398A3 (en) | 2006-10-26 |
US20060018800A1 (en) | 2006-01-26 |
EP1718410B1 (en) | 2013-01-09 |
EP1718410A4 (en) | 2008-02-27 |
WO2005072398A2 (en) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7618591B2 (en) | Specimen sample collection device and test system | |
US7927548B2 (en) | Specimen sample collection device and test system | |
US8025851B2 (en) | Specimen sample collection device and test system | |
US6663831B2 (en) | “One-device” system for testing constituents in fluids | |
US6365417B1 (en) | Collection device for lateral flow chromatography | |
US6998273B1 (en) | Collection device for lateral flow chromatography | |
JP4667389B2 (en) | Sample collection cup with integrated sample analysis system | |
US9198641B2 (en) | Specimen sample collection system | |
US10119968B2 (en) | Self-contained diagnostic test with advanceable test strip | |
US6248598B1 (en) | Immunoassay that provides for both collection of saliva and assay of saliva for one or more analytes with visual readout | |
EP1549210B1 (en) | Integrated confirmation sample in a body fluid test device | |
JP4889498B2 (en) | High-speed sample analysis and storage device and method of use | |
US20040184954A1 (en) | Lateral flow immunoassay devices for testing saliva and other liquid samples and methods of use of same | |
US20090155124A1 (en) | Collection and assay device for biological fluid | |
CN1823273B (en) | Compact analyte testing cassette with true positive and negative analyte controls | |
EP2344623B1 (en) | Collection and assay device for biological fluid | |
AU2022204801A1 (en) | Test strip for detecting analyte in sample | |
AU2002338364B2 (en) | A "one-device" system for testing constituents in fluids | |
AU2002338364A1 (en) | A "one-device" system for testing constituents in fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |